





































































In  particular,  it  has  been  previously  shown  that  B‐cell  receptor  (BCR)  repertoire,  expressed  by 
clonal B‐cells involved in HCV‐associated NHL, is constrained to a limited number of variable heavy 
(VH)‐ and  light (VL)‐chain genes. Among these, the VK3‐20  light chain  idiotype has been selected 
as a target for passive as well as active immunization strategy. 











Hepatitis C virus  (HCV)  is an enveloped, positive‐strand RNA virus of  the Flaviviridae  family. The 
viral genome consists of a 9.6 kb RNA molecule, containing a large open‐reading frame flanked by 
5’ and 3’ non‐translated regions (NTRs) [1].  










Once  released  from NS2, NS3  acts a multifunctional protein, with  a N‐terminal  serine protease 





















Indeed,  the  liver  is  the major  site of HCV  replication, however, evidence exists  for extrahepatic 
reservoirs,  including  peripheral  blood  cells,  epithelial  cells  in  the  gut  and  the  central  nervous 
system [13,15,16].  
HCV particles bind several host‐cell receptors, including the CD81 tetraspannin [17,18], the human 
scavenger  receptor  SR‐BI  [19],  claudin‐1  (CLDN‐1)  [20]  and  occludin  (OCLN)  [21],  as  well  as 
glycosaminoglycans [22] and the low‐density lipoprotein receptor (LDL‐R) [23].  
The fusion of viral and cellular membranes  leads to the  intra‐cytoplasmatic release of the single‐













in  determining  progression  of  chronic  hepatitis  C  to  liver  cirrhosis  and  HCC,  a  process  that 
frequently takes several decades [24].  
The  molecular  mechanisms  underlying  HCC  development  involve  several  indirect  mechanisms 
including the interplay between chronic inflammation, steatosis, fibrosis, oxidative stress and their 
pathological consequences [24].  
Indeed,  HCC  development  is  associated  with multistep  processes  including  the  occurrence  of 
somatic mutations, loss of tumor suppressor genes and possibly the activation or over‐expression 
of proto‐oncogenes [24]. 
More  recently,  the  virus  has  been  identified  as  one  of  the major  risk  factors  for  type  II mixed 
cryoglobulinemia  (MC),  an  autoimmune  disease  characterized  by  the  clonal  expansion  of 






Several  studies  have  contributed  to  establish  the  causative  role  of  HCV  infection  in  the 














translocation observed  in 85% of  the patients affected by HCV‐related  type  II MC might  lead  to 




called idiotype,  Id) of the  immunoglobulin (Ig) produced by the B cell clone and expressed on  its 
surface as B cell receptor (BCR). According to the variety of Ids identified, the lymphoproliferative 
















One strategy  is to generate  idiotype‐specific monoclonal antibodies  (MAbs) to be employed  in a 
selective  passive  immunization  and,  in  this  regard,  highly  reactive  MAbs  specific  for  VK3‐20 
idiotype of a subject with HCV infection and type II MC associated NHL have been generated [43].  
The alternative  strategy  is  to use  the  idiotype as a vaccine molecule  in order  to elicit an active 
humoral/cellular  immune  response  as  preventive  and/or  therapeutic  approach  against  the 
expansion of the B cell clone sustaining the HCV‐associated NHL [44‐46].  
Indeed,  idiotype  vaccines  have  already  proven  to  be  effective  in  inducing  specific  immune 
responses which  are  able  to  kill  in  vivo  follicular  lymphoma  cells  that had  survived pre‐vaccine 
chemotherapy [47,48], ultimately resulting in prolonged survival of responding patients [49].  
Several ongoing Phase  I/II clinical  trials  for  the  treatment of  tumors of hematological origin are, 
indeed,  based on idiotype vaccines. 




idiotype vaccine  (conjugated  to keyhole  limpet hemocyanin  (KLH) plus granulocyte macrophage 
colony  stimulating  factor  (GM‐CSF))  in preventing  relapse of  follicular  lymphoma  in  responding 
patients (ClinicalTrials.gov Identifier: NCT00530140). 
Finally, a randomized Phase  II clinical  trial  is ongoing  to evaluate  the outcome of a combination 
strategy  based  on  infusion  of  CD3/CD28  autologous  T  cells,  primed  ex  vivo  with  Id‐KLH,  and 
vaccine  administration  in  patients  with  multiple  myeloma  (ClinicalTrials.gov  Identifier: 
NCT01426828).  






Yet,  a  higher  frequency  of  idiotype  sharing  exists  among  patients  with  HCV‐associated  NHL, 
allowing  the use of  limited  Ids  for  vaccine  therapy,  thus, overcoming  the  issue of  complex and 
time‐consuming approach needed for vaccines production.  
1.5. Systems biology in vaccine development 





Importantly,  there  are  two  major  approaches  to  systems  biology:  a  top‐down  view  in  which 
potential  permutations  predicted  by  experimentally  formed  knowledge  are  speculated  with  a 
deductive  approach;  conversely,  and  inductive  approach  is  often  applied  in  clinical  research 




the  innate  and  early  adaptive  immune  response  induced  by  a  vaccine  molecule  in  human 
monocyte‐derived dendritic cells  (MDDCs), as well as whole peripheral blood mononuclear cells 
(PBMCs), using ex vivo experimental setting [51‐53].  
This  systems  biology  approach  involves  high‐throughput  technologies  such  as  global  gene 
expression profiling, multiplex analysis of  cytokines and  chemokines, as well as multiparameter 
flow cytometry, combined with computational modeling  [54‐58].  
Such  approach  provides  detailed  level  of  investigation  to  analyze  the  network  of  interactions 
between a vaccine molecule and the innate and adaptive immune response [59,60].  










In  the present study, we performed a multiparametric analysis of  the  innate and early adaptive 
immune  response  induced  after  ex  vivo  stimulation  of  human  PBMCs with  VK3‐20  light  chain 
protein,  the  idiotype most  frequently  identified  on  B  cell  clones  sustaining  the HCV‐associated 
type II MC and NHL.  
This  objective  has  been  pursued  using  freshly  isolated  circulating  human  PBMCs,  on which we 
performed  gene  expression  profiling  analysis  as  well  as  multiparameter  flow  cytometry  and 
multiplex analysis of cytokines. 
A preliminary study of the  innate and early adaptive  immune signature  induced by recombinant 
VK3‐20 protein was performed on whole PBMCs,  as well  as MDDCs  from  15  enrolled  subjects, 
including 10 HCV seropositive subjects and 5 healthy controls [66]. 
Subsequently,  the  effect  of  a  conjugated  form  of VK3‐20  (i.e. VK3‐20‐KLH)  protein  on  immune 
response was  studied on whole PBMCs  isolated  from a  second  cohort of  subjects,  including 10 
HCV seropositive subjects and 5 healthy controls (Petrizzo et al., submitted). 
Finally, to further  investigate the effect of VK3‐20 protein ex vivo “vaccination” on whole PBMCs 
after 24h or 6 days  incubation,  the gene expression profile of  samples  from 5 HCV  seropositive 
subjects  and  4  healthy  controls  was  examined.  In  parallel,  molecular  detection  of  immune 
signature  induced by VK3‐20 protein  stimulation after 24h or 6 days  incubation was performed 
(Petrizzo et al., submitted). 











Fifteen  subjects  were  enrolled  for  preliminary  study  of  immune  signature  induced  by  VK3‐20 
































The  stimulation  with  VK3‐20  protein  induced  a  trend  of  increased  expression  of  the 
activation/maturation markers in all circulating cells from the HCV seropositive subjects, although 








Moreover, the  levels of IL‐2, gamma  interferon (IFN‐γ), tumor necrosis factor alpha (TNF‐α),  IL‐6, 
IL‐4 and IL‐10 were assessed  in the supernatant of PBMCs stimulated with the recombinant VK3‐
20 protein.  








































































































Fig.  5.  Cytokines  analysis  in  supernatants  of  PBMCs  from  control  subjects  induced  by  the  indicated 
concentrations of VK3‐20 and LPS. * P < 0.05, ** P < 0.01, *** P < 0.001. 
 
Fig.  6.  Cytokines  analysis  in  supernatants  of  PBMCs  from  HCV  seropositive  subjects  induced  by  the 
indicated concentrations of VK3‐20 and LPS. * P < 0.05, ** P < 0.01, *** P < 0.001. 
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SAMPLE CODE SEX HCV RNA (IU/ml) CRYOCRIT % RF TEST (IU/ml) WAALER‐ROSE TEST NHL
S.R. F NEG. NEG. NEG. NEG. NEG.
A.I. F NEG. NEG. NEG. NEG. NEG.
S.F. M NEG. NEG. NEG. NEG. NEG.
C.R. F NEG. NEG. NEG. NEG. NEG.
A.C. F NEG. NEG. NEG. NEG. NEG.
N.L. M 1900 1.50 31.2 POS. NEG.
M.M.L. F 629000 0.5 127 POS. NEG.
F.M. F 500000 0.1 3.9 NEG. NEG.
P.M. F 700000 2 607 POS. NEG.
V.A. M 3000000 0.5 7.7 NEG. NEG.
B.E. M 9000 1.1 670 POS. NEG.
D.N. M 1130000 0.3 122.00 POS. NEG.
L.M.R. M 5850000 0.8 114 POS. NEG.
D.B.A. M 2340000 0.6 112 POS. NEG.
B.D. F HCV RNA neg./HIV RNA pos. 0.2 12 NEG. NEG.  
 
         3.3. Immune signature induced by a conjugated form of VK3‐20 protein 
Our previous study showed that VK3‐20  induced higher  levels of specific Th2 cytokines  in PBMCs 









Indeed,  the  immune‐potentiating  effect  of  KLH  carrier  protein  on  tumor  antigens  has,  already, 




for  phenotypic  analysis  by  flow  cytometry  and  the  expression  of  surface maturation/activation 




Fig.  7.  Expression  of  surface markers  on  ex  vivo  activated  cells  from  a  healthy  control.  PBMCs were 





































The  expression  of  activation  markers  and  costimulatory  molecules  was  largely  comparable 
between healthy controls and HCV seropositive subjects, with minor differences between VK3‐20 
and  VK3‐20‐KLH  treatment  (Fig.  10‐11).  However,  the  stimulation  with  VK3‐20‐KLH  conjugate 



































































































































































































































































































































































































































In  addition,  the  levels  of  IL‐2,  IL‐5,  IL‐6,  IL‐10,  IFN‐γ  and  TNF‐α were  assessed  by  ELISA  in  the 
supernatant  of  stimulated  PBMCs.  Both  VK3‐20  protein  and  VK3‐20‐KLH  conjugate  induced  a 
significant production of TNF‐α, IL‐6 and IL‐10 (p < 0.05) with no statistically significant differences; 
moreover, the  level of  induction  in samples from healthy controls and HCV seropositive subjects 
was largely comparable (Fig. 12‐13). 
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According  to  filtering  parameters  described  in  Materials  and  Methods  section,  6’562  genes 
differentially expressed were selected for the unsupervised analysis. 
A  clear  cut  separation  in  two  main  clusters  matching  the  “time  point”  (24h  or  6  days)  was 
observed  (Fig. 15). Moreover, within  the 24h cluster a clear  separation between PBS  treatment 







































controls  (light  blue)  and  5  HCV  seropositive  subjects  (light  red).  Red  indicates  over‐expression;  green 






















intermediate  between  the  HCV+  and  HCV‐  samples,  with  an  overall  down‐regulation  of  the 
identified genes.  
Concerning  the HCV+  subjects, most  of  the  108  up‐regulated  genes  fell  into  several  biological 
functions, including the defense and inflammatory responses (Table 3). The list of genes related to 
the inflammatory response is shown in Table 4.  
Most  of  the  remaining  40  genes were  not  annotated  or  associated  to  any  significant  cluster‐
function.  











































GENE ONTOLOGY TERM COUNT PERCENTAGE  P‐VALUE
Response to wounding 17 15.88 9.36E‐08
Glycosylation site: N‐linked (GlcNAc...) 46 42.99 2.94E‐07
Glycoprotein 47 43.92 3.22E‐07
Vacuole 12 11.21 5.73E‐07
Lytic vacuole 10 9.34 7.93E‐06
Lysosome 10 9.34 7.93E‐06
Disulfide bond 34 31.77 1.09E‐05
Defense response 15 14.01 1.74E‐05








wise  comparisons  between  stimulated  (VK3‐20  treated)  and  non‐stimulated  (PBS)  PBMCs  from 
both  HCV  seropositive  subjects  and  healthy  controls.  Integrated  analyses  were  performed  to 
identify the signature processes and pathways  induced by VK3‐20 treatment after 24 hours or 6 
days and to compare VK3‐20 treatment effects at 24 hours and 6 days.  










sets  in  stimulated  and  non‐stimulated  PBMCs  from  HCV  seropositive  subjects  (light  red)  and  healthy 








Up‐regulated  genes  were  analyzed  using  DAVID  Bioinformatics  Database 
(http://david.abcc.ncifcrf.gov) for associations with particular Gene Ontology (GO) terms. Indeed, 


















































































sets  in  stimulated  and  non‐stimulated  PBMCs  from  HCV  seropositive  subjects  (light  red)  and  healthy 
controls  (light  blue)  after  6  days  incubation.  The  expression  pattern  of  the  genes  is  shown,  each  row 
represents a single gene. 
 
The  genes  up‐regulated  after  treatment with  VK3‐20,  showing  the most  significant  association 
with the Response to Wounding GO term are listed in Table 6.  
 




















VK3‐20  induced a   gene expression profile  that was more similar within each group of analyzed 






sets  in stimulated PBMCs after 24h and 6 days  incubation. The expression pattern of the genes  is shown, 
each row represents a single gene. 
 
The  genes  up‐regulated  after  24h  of  stimulation  with  the  VK3‐20  protein  were  significantly 
associated with Cytokine Activity (Table 7A).  
On  the other hand, most of  the 641 genes up‐regulated after 6 days  incubation,  clustered  into 
several groups related to cell cycle activity, including: mitosis, nuclear division, nucleotide binding, 










































































LPS, as a positive activator of genes  involved  in the pathway of  immune response, was analyzed 
and compared to the gene expression profile of PBMCs ex vivo stimulated with VK3‐20.  









Fig. 20 Heat maps of  the  gene  signature  identified by Class Comparison Analyses. Analyses  comparing 
gene  sets  in  LPS  stimulated  PBMCs  from  HCV‐  subjects  (A)  and  VK3‐20  stimulated  PBMCs  from  HCV‐ 










It  is  relevant  that  180  genes  were  up‐regulated  after  treatment  with  both  LPS  and  VK3‐20, 




in the pathway of  immune response,  including CD83  (see  figure 7), which plays a central role  in 
antigen presentation, and CD274, which  is  specifically up‐regulated on macrophages and DCs  in 
response  to LPS,  inducing  IL‐10 production, which,  in  turn,  inhibits CD4+ T cell  function  [75‐79]. 
Table 9 summarizes the results obtained. 
Interestingly, among genes down‐regulated, only, after LPS treatment, we found CD86 (see figure 
7), which  is  involved  in costimulatory signal, essential for T cell proliferation and IL‐2 production, 
by binding CD28 for stimulatory signal or CTLA‐4 for inhibitory signal [80]. 
 














































































Gene expression  changes  induced by ex vivo “vaccination” after 24h or 6 days  incubation were 
obtained by subtracting the log2 expression value induced  by PBS (non‐stimulation/baseline) from 
the one induced by VK3‐20.  
The  human  pathway  lists  were  determined  by  "Ingenuity  System  Database",  setting  the 
significance threshold of t‐test at 0.05.  
Samples  from  VK3‐20‐stimulated  PBMCs  after  24h  showed  a  strong  up‐regulation  of  genes 





rapid  inflammatory  reaction  triggered  by  infection,  tissue  injury,  neoplastic  growth  and 
immunological disorders. This  is  characterized by  the  increase of  inflammatory  factors  (such  as 
pro‐inflammatory  cytokines  IL‐1,  IL‐6,  TNF‐α)  and  the  change  in  the  concentration  of  several 






On  the  other  hand,  at  6  days  post‐stimulation,  genes  involved  in  the  Role  of  Tissue  Factor  in 
Cancer,  ILK  (integrin  linked  kinase)  Signaling,  IL‐17  Signaling  and  G‐Protein  Coupled  Receptor 
Signaling ranked at the top and were up‐regulated in PBMCs (Fig. 22).  
Among  such  “late”  pathways,  the  IL‐17  Signaling  is  relevant  to  the  present  study.  IL‐17,  also 
referred to as IL‐17A, is a member of a family of cytokines primarily secreted by T cells [83], whose 
function is essential to a subset of CD4+ T cells called T helper 17 (Th17) cells. IL‐17 promotes the 








and  the  JAK/PI3K/AKT,  that  lead  to  the  induction  of  pro‐inflammatory  cytokines,  chemokines, 
matrix metalloproteinases  and  anti‐microbial  peptides  [85].  Indeed,  IL‐17  is  a  unique  cytokine, 
playing a central role in integrating adaptive and innate immune responses.  
Other  significant canonical pathways positively modulated after VK3‐20  stimulation are  listed  in 
Figures 21 and 22. 
 

































Among  differentially  expressed  genes, modulated  by  VK3‐20  after  24h  and  6  days  incubation, 
Ingenuity Pathways Analysis  identified a  specific network  related  to  the  Inflammatory Response 
(Fig. 24‐27). The analysis showed  that VK3‐20  induced a gene signature  in which NF‐κB  (nuclear 
factor kappa‐light‐chain‐enhancer of activated B cells) protein complex plays a crucial role. Indeed, 
NF‐κB complex  is known  to be  involved  in cellular  responses  to several stimuli,  including stress, 
cytokines, ultraviolet irradiation and bacterial or viral antigens [86]. NF‐κB protein complex is, also, 































































































In  particular,  genes whose  function  is  involved  in  inflammatory  response,  cellular  growth  and 
proliferation, cancer and immunological disease ranked at the top and were up‐regulated in VK3‐
20 stimulated PBMCs after 24h (Fig. 28).  
On  the  other  hand,  genes  involved  in  immune  cell  trafficking,  inflammatory  response, 
hematological system development and function were up‐regulated  in VK3‐20 stimulated PBMCs 
after 6 days (Fig. 29).  













































after 24h  incubation  identified 58 CGAP  genes differentially expressed. Among  them, 36  genes 
were  shown  to  be  up‐regulated  and  22  genes were  down‐regulated  in  stimulated  PBMCs  (Fig. 
31A).  
The same analysis performed on samples from HCV seropositve subjects identified 54 CGAP genes 





The  same  analysis  on  samples  from HCV  seropositve  subjects  identified  27  genes  differentially 
expressed.  Among  them,  11  genes were  shown  to  be  up‐regulated  and  16  genes were  down‐





































Fig.  31.  Heat  map  of  the  immune  gene  signature  identified  by  Class  Comparison  Analysis.  Analysis 








































































































































































































































































Fig.  32.  Heat  map  of  the  immune  gene  signature  identified  by  Class  Comparison  Analysis.  Analysis 













































































































































characterized  by  a  significant  up‐regulation  of  genes  of  the  cytokine  and  cytokine  receptor 
families, as well as of downstream signaling cascades, including IL‐1, IL‐6, OSM (oncostatin M), IL‐




to  be  produced  by  activated  macrophages,  it  is  an  important  mediator  of  the  inflammatory 
response  and  is  involved  in  several  cellular  activities,  including  cell proliferation, differentiation 
and apoptosis [94].  
In particular, IL‐1 shares with TNF‐α similar receptor mechanisms and downstream pathways [95]. 
Indeed,  the potent pro‐inflammatory activity of  these cytokines  is  triggered by  the activation of 
the  same  set  of  transcription  factors  (i.e.  MAPK8/JNK  and  NF‐kB)  [95].  The  individual  signal 




receptor  (IL1R)  upon  stimulation,  participating  in  IL1‐mediated  up‐regulation  of NF‐kB  through 
TRAF6 [91]. 
Moreover, we found that TRAF1 was, also, up‐regulated [92]. The protein is a member of the TNF 
receptor  associated  factor protein  family.  TRAF1  is  able  to  form  a heterodimeric  complex with 
TRAF2, which is required for TNF‐alpha‐mediated activation of MAPK8/JNK and NF‐kB.  
Furthermore, several genes specifically induced by IL‐1 and TNF‐α were found to be up‐regulated 
by  VK3‐20  stimulation,  including  TNFAIP6, which  plays  an  important  role  in  protease  network 
associated  with  inflammation  [90]  and  BCL2‐related  protein  A1  (BCL2A1),  which  is  a  direct 
transcription target of NF‐kB [96]. Finally, NFKB2 subunit was found to be up‐regulated, as well. 
Besides the up‐regulation of several mediators of  innate  immunity, such as chemokines (i.e. IL‐8) 


















9  (TNFRSF9)  [99,100], confirms our preliminary  results,  stressing  the ability of VK3‐20  to  induce 
the expression of activation markers and co‐stimulatory molecules on circulating APCs after 24h 
incubation [66].  
Indeed,  it  is well known that CD80, which  is found on activated B cells and monocytes,  is able to 
provide a costimulatory signal necessary for T cell activation and survival [101].  
Moreover, the activation of T cells, both in vivo and in vitro, is known to induce the expression of 
CD69,  which  appears  to  be  the  earliest  inducible  cell  surface  glycoprotein  acquired  during 
lymphoid  activation  [102].  CD69  is  involved  in  T  cell  proliferation,  and  works  as  a  signal‐
transmitting receptor in lymphocytes [103].  
Finally, TNFRSF9  (CD137)  is known  to be expressed by activated T cells, DCs,  follicular dendritic 
cells,  natural  killer  cells,  granulocytes  and  cells  of  blood  vessel walls  at  sites  of  inflammation. 
CD137 enhances T cell proliferation, IL‐2 secretion, survival and cytolytic activity. CD137 has been 

























GENE ONTOLOGY TERM  COUNT  PERCENTAGE   P‐VALUE 
Response to wounding  15  45.4  4.17E‐12 
Inflammatory response  11  33.3  2.25E‐09 
Programmed cell death  12  36.3  7.91E‐08 
Defense response  12  36.3  8.45E‐08 
Regulation of cell proliferation  13  39.3  1.06E‐07 
Cytokine‐mediated signaling pathway  6  18.1  5.80E‐07 
Acute‐phase response  5  15.1  2.22E‐06 
IL‐1 receptor binding  4  12.1  5.50E‐06 
Positive regulation of cell communication  8  24.2  9.41E‐06 
Immunoregulation  3  9  4.01E‐05 
Acute inflammatory response  5  15.1  7.97E‐05 
Positive regulation of T cell proliferation  4  12.1  1.04E‐04 
Regulation of T cell activation  5  15.1  1.58E‐04 
Positive regulation of mononuclear cell proliferation  4  12.1  3.06E‐04 
Cytokine activity  5  15.1  8.73E‐04 
 
 
INFLAMMATORY RESPONSE       
AFFYMETRIX_EXON_GENE_ID  GENE NAME  GENE SYMBOL  MODULATION 
8071899  adenosine A2a receptor  ADORA2A  UP 
8045688  tumor necrosis factor, alpha‐induced protein 6  TNFAIP6  UP 
8044574  interleukin 1 receptor antagonist  IL1RN  UP 
8054712  interleukin 1, alpha  IL1A  UP 
8054722  interleukin 1, beta  IL1B  UP 
7931914  interleukin 2 receptor, alpha  IL2RA  UP 
8131803  interleukin 6 (interferon, beta 2)  IL6  UP 
8077786  interleukin‐1 receptor‐associated kinase 2  IRAK2  UP 
7924499  toll‐like receptor 5  TLR5  DOWN 
7960947  alpha‐2‐macroglobulin  A2M  DOWN 
8058765  fibronectin 1  FN1  DOWN 
 
CYTOKINE‐MEDIATED SIGNALING PATHWAY    
AFFYMETRIX_EXON_GENE_ID  GENE NAME  GENE SYMBOL  MODULATION 
8035351  Janus kinase 3  JAK3  UP 
8054712  interleukin 1, alpha  IL1A  UP 
8054722  interleukin 1, beta  IL1B  UP 
8131803  interleukin 6 (interferon, beta 2)  IL6  UP 
8077786  interleukin‐1 receptor‐associated kinase 2  IRAK2  UP 



















PROGRAMMED CELL DEATH      
AFFYMETRIX_EXON_GENE_ID  GENE NAME  GENE SYMBOL  MODULATION 
7990818  BCL2‐related protein A1  BCL2A1  UP 
8163825  TNF receptor‐associated factor 1  TRAF1  UP 
8071899  adenosine A2a receptor  ADORA2A  UP 
8054712  interleukin 1, alpha  IL1A  UP 
8054722  interleukin 1, beta  IL1B  UP 
7931914  interleukin 2 receptor, alpha  IL2RA  UP 
8131803  interleukin 6 (interferon, beta 2)  IL6  UP 
8075316  oncostatin M  OSM  UP 
8130556  superoxide dismutase 2, mitochondrial  SOD2  UP 
8066214  transglutaminase 2  TGM2  UP 
8157582  gelsolin (amyloidosis, Finnish type)  GSN  DOWN 










































The  above mentioned  results  have  been  further  confirmed  by  parallel  cytokine  evaluation  in 





























to  HCV‐related  B  cell  NHL,  here  we  report  the  results  of  a multivariate  and multiparametric 
analysis  of  the  innate  and  early  adaptive  immune  response  induced  in  PBMCs  from  HCV 
seropositive  subjects  and  healthy  controls,  following  ex  vivo  “vaccination”  with  the  most 
represented VK3‐20 light‐chain protein idiotype, expressed by clonal B cells of HCV‐related type II 
MC as well as NHL [43].  
The  immune  signature  induced  by  VK3‐20  and/or  VK3‐20‐KLH  was  evaluated,  based  on  flow 
cytometry analysis as well as cytokine profile analysis of stimulated PBMCs.  
Preliminary  results  showed  that  the basal and VK3‐20‐induced expression of activation markers 
and  co‐stimulatory molecules  in  the  evaluated  circulating  antigen  presenting  cells  (APCs) was 
largely comparable between HCV seropositive subjects and healthy controls [66].  
Overall,  the  activation markers  showed  a  trend  of  increased  expression  in  all  circulating  cells, 
although  the  most  evident  and  consistent  pattern  was  observed  in  the  CD123+  pDCs  and/or 
CD11c+ mDCs [66].  
No significant difference was observed  in results obtained from monocyte derived dendritic cells 
(MDDCs)  and  circulating  APCs,  confirming  our  previous  results  and  results  from  other  groups 
[51,55,57,105]. The overall expression pattern  suggested maturation/activation  induced by VK3‐
20, although  for  some  specific markers and  in  some patients  the  trend did not  reach  statistical 
significance.  
Results  obtained  in  parallel with  lipopolysaccharide  (LPS),  used  as  a  positive  activation  factor, 
confirmed  the  responsiveness of  circulating APCs  from both groups analyzed  in  the preliminary 
analysis [66].  
Nonetheless, some HCV+ individuals showed a complete lack of maturation induced by VK3‐20 in 
circulating  APCs,  strongly  suggesting  the  need  for  individual  evaluations  to  identify  possible 
impairments in response to the specific immunogen.  
These preliminary  results confirm and extend data  from others  showing a normal expression of 
surface molecules involved in antigen‐specific T cell activation on immature and mature DCs from 
HIV‐1‐infected  and  HCV/HIV‐co‐infected  individuals  [106‐108].  Furthermore, monocyte  derived 












Indeed,  the  production  of  IFN‐γ  is  known  to  be  inhibited  by  IL‐10  [112],  with  a  sequential 
detrimental effect on  the  IL‐12‐mediated  induction of  IFN‐γ production by NK and T cells  [113]. 
Therefore,  the  high  levels  of  IL‐10  induced  by  VK3‐20  could  explain  the  lack  of  increased 
production  of  IFN‐γ  in  both  groups.  The  very  similar  response  observed  in  HCV  seropositive 
subjects, regardless of the diagnosis of type II MC or NHL, would suggest the absence of an in vivo 
priming for the VK3‐20.  




Our  results  indicate  that  the  expression  of  activation markers  and  costimulatory molecules  on 
monocytes  and  CD11c+  mDCs  was  largely  comparable  between  healthy  controls  and  HCV 
seropositive subjects, with no statistically significant differences between VK3‐20 and VK3‐20‐KLH 
treatment.  
In addition, the  levels of  IL‐2,  IL‐5,  IL‐6,  IL‐10,  IFN‐γ and TNF‐α were assessed  in supernatants of 
stimulated  PBMCs.  Both  VK3‐20  protein  and  VK3‐20‐KLH  conjugate  induced  a  significant 
production  of  TNF‐α,  IL‐6  and  IL‐10  (p  <  0.05) with minor  differences,  suggesting  comparable 
effects exerted by VK3‐20‐KLH and VK3‐20 treatment.  












The primary unsupervised analysis  showed a distinct gene  signature pattern  induced by VK3‐20 
treatment after 24h or 6 days incubation. Moreover, VK3‐20 treatment induced the segregation of 
the  HCV‐related  samples  from  control  samples,  indicating  the  identification  of  specific  gene 
signature patterns peculiar to the HCV‐status. 
A  supervised  analysis was  performed  by  pair‐wise  comparisons  between  stimulated  and  non‐




them,  300  genes  were  shown  to  be  up‐regulated  in  stimulated  PBMCs,  which  were  further 
analyzed  using  the  DAVID  Bioinformatics  Database  for  annotation  and  50  of  them  showed  a 
significant association with the Immune Response Gene Ontology term. 
The analysis comparing gene sets in stimulated and non‐stimulated PBMCs after 6 days incubation 
identified  149  genes  differentially  expressed.  The  up‐regulated  genes  showed  a  significant 
association with the Response to Wounding GO term.  
Finally, the analysis comparing gene sets in stimulated PBMCs after 24h and 6 days identified 851 





Indeed,  samples  from  stimulated  PBMCs  after  24h  showed  a  positive  modulation  of  genes 
involved  in Communication between  Innate and Adaptive  Immune Cells, Acute Phase Response 
Signaling,  LXR/RXR  Activation,  IL‐6  Signaling,  Dendritic  Cell  Maturation,  Role  of  Cytokines  in 
Mediating Communication between  Immune Cells, TREM1 Signaling. Whereas, genes  involved  in 
the  pathways  of  ILK  Signaling,  IL‐17  Signaling,  G‐Protein  Coupled  Receptor  Signaling  were 
positively modulated in PBMCs from samples stimulated for 6 days.  


















Moreover, gene expression data  showed  the up‐regulation of  surface activation markers of  the 
immune  cells,  such  as CD123, CD80, CD69  and  TNFRSF9,  confirming our  preliminary  results  on 
immune signature induced by VK3‐20 stimulation after 24h incubation [66].  
In summary, we demonstrated that systems biology approaches not only allow the observation of 
a  global picture of  vaccine‐induced  innate  immune  responses but  can be,  also, used  to predict 
subsequent adaptive immune response. 
In particular, our results strongly suggest the  induction of the  innate and early adaptive  immune 
response  in  PBMCs  ex  vivo  stimulated  with  the  most  represented  VK3‐20  light‐chain  protein 















Peripheral  blood  was  obtained  by  venipuncture  from  HCV  seronegative  volunteers  and  HCV 
seropositive  subjects. All human  specimens were obtained at  the  Infectious Disease Unit of  “G. 




six‐well plates  at  a  concentration of  approximately 1x107  cells/well  in  a maximum  volume of 3 
ml/well for induction [56,114]. Isolated PBMCs were then cultured for 24h (short‐term culture) or 
for 6 days (medium‐term culture) in RPMI 1640 medium. 
Alternatively, MDDCs were  generated  as  described  previously  [114], with minor modifications. 
Briefly,  isolated PBMCs were enriched for CD14+ monocytes by negative selection with a cocktail 





DC  culture medium  supplemented with  50  ng  of  recombinant  granulocyte‐macrophage  colony‐




with  2  mM  L‐glutamine  (Sigma),  10%  fetal  calf  serum  (Life  Technologies)  and  2% 
penicillin/streptomycin (5,000 I.U./5mg per ml, MP Biomedicals). Recombinant interleukin‐2 (rIL‐2; 







with  2 mM  L‐glutamine  (Sigma),  1%  non‐essential  amino  acids  (Life  Technologies),  1%  sodium 










20  protein  (15  µg/ml)  or  the  recombinant  VK3‐20‐KLH  (15  µg/ml)  protein,  provided  by  Areta 
International  (Gerenzano,  Italy).  In  parallel,  cells were  pulsed with  8  μg/ml  of  LPS,  as  positive 
control.  Furthermore, PBMCs were  incubated  for  6 days  (medium‐term  culture) with  the  same 









antibodies  specific  for  CD40,  CD80,  CD83,  CD86,  HLA‐DR,  CD11c,  CD123  and  CD14  (BD 
Pharmingen, San Diego, CA), washed and  then analyzed with a FACScalibur  flow  cytometer  (BD 















Total  RNA  from  PBMCs  was  purified  using  the  RNeasy  Mini  Kit  (Qiagen)  according  to 
manufacturer's instructions. The purity of total RNA preparation was verified by 260:280 nm ratio 









After  hybridization  on Human Gene  1.0  ST Arrays  (Affymetrix)  for  16h  at  45°C  at  60  rpm  in  a 
Hybridization Oven  640  (Affymetrix),  slides were washed  and  stained  on  a  Fluidics  Station  450 
(Affymetrix). Scanning was performed on a GeneChip Scanner 3000 7G (Affymetrix) and Affymetrix 
GCOS  software was used  to perform  image analysis and generate  raw  intensity data  (CEL  files). 
Initial data quality was assessed by background  level and pairwise correlation among samples. A 
log2 base transformation was applied to the data before the arrays were normalized. Microarray 












For  the  unsupervised  analysis  a  low‐stringency  filtering  was  applied,  selecting  the  genes 





Supervised  class  comparison was  performed  using  BRB  ArrayTool  developed  at  NCI,  Biometric 
Research  Branch,  Division  of  Cancer  Treatment  and  Diagnosis.  Three  subsets  of  genes  were 
explored.  The  first  subset  included  genes  up‐regulated  in  stimulated  (VK3‐20  treated)  PBMCs 
compared  to  non‐stimulated  (PBS  treated)  PBMCs  after  24h  incubation,  the  second  subset 
included  genes  up‐regulated  in  stimulated  PBMCs  compared  to  non‐stimulated  PBMCs  after  6 
days  incubation,  the  third  subset  included  genes  up‐regulated  in  stimulated  PBMCs  after  24h 
incubation compared  to  stimulated PBMCs after 6 days  incubation,  from both HCV  seropositive 
subjects and healthy controls.  
Class comparison analyses were tested for an univariate significance threshold set at a p‐value < 
















indirect relationships between genes, based on  interactions contained  in the  Ingenuity Pathways 
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Abstract
Hepatitis C virus (HCV) is one of the major risk factors for chronic hepatitis, which may progress to cirrhosis and
hepatocellular carcinoma, as well as for type II mixed cryoglobulinemia (MC), which may further evolve into an
overt B-cell non-Hodgkin’s lymphoma (NHL).
It has been previously shown that B-cell receptor (BCR) repertoire, expressed by clonal B-cells involved in type II
MC as well as in HCV-associated NHL, is constrained to a limited number of variable heavy (VH)- and light (VL)-
chain genes. Among these, the VK3-20 light chain idiotype has been selected as a possible target for passive as
well as active immunization strategy.
In the present study, we describe the results of a multiparametric analysis of the innate and early adaptive immune
response after ex vivo stimulation of human immune cells with the VK3-20 protein. This objective has been pur-
sued by implementing high-throughput technologies such as multiparameter flow cytometry and multiplex analy-
sis of cytokines and chemokines.
Introduction
Hepatitis C virus (HCV) is a Hepacivirus of the Flaviviri-
dae family, mainly involved in hepatic disorders, includ-
ing chronic hepatitis which may progress to cirrhosis in
about 10-20% of cases and further to hepatocellular car-
cinoma in 1-5% of cirrhotic patients [1].
Subsequently, the virus has been implicated as one of
the major risk factors for type II mixed cryoglobuline-
mia (MC), an autoimmune disease that may evolve into
an overt B-cell non-Hodgkin’s lymphoma (NHL) in
about 10% of MC patients [2-5]. Several studies have
contributed to establish the causative role of HCV infec-
tion in the etiopathogenesis of MC, showing the
presence of the viral RNA and/or anti-HCV antibodies
in a range of 70 to 100% of MC [6-8]. Furthermore, the
clinical evolution of MC is closely linked to the natural
history of the underlying HCV chronic infection [9,10].
The most accredited pathogenetic mechanism of MC
during HCV chronic infection is the persistent immune
stimulation sustained by viral proteins which, in turn,
may result in production of cross-reactive autoantibo-
dies, including cryoglobulins [11,12]. Chronic stimula-
tion of the B-cell by HCV epitopes may produce the
expansion of B-cell subpopulations with dominant
genetic characteristics. In particular, the interaction
between HCV E2 protein and CD81 molecule, an almost
ubiquitous tetraspannin present on B-cell surface, has
been shown and it may lead to a strong and sustained
polyclonal stimulation of B-cell compartment [13].
Furthermore, the t (14,18) translocation observed in
85% of the patients affected by HCV-related type II MC
might lead to abnormally elevated expression of Bcl-2
protein with consequent inhibition of apoptosis and
increased B-cell survival [14]. This multistep process
may ultimately lead to B-cell NHL as late complication
of the MC syndrome [9,15].
The clonality of expanded B cells can be defined by
the analysis of the antigen-binding region (so called
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idiotype, Id) of the immunoglobulin produced and
expressed by the B-cell clone. According to the variety
of Ids identified, the lymphoproliferative disorder may
be sustained by mono-, oligo- or polyclonal B cells. It
has been previously demonstrated that the B-cell recep-
tor (BCR) repertoire expressed by clonal B-cells involved
in HCV-associated type II MC as well as in NHL is not
random, with V1-69, V3-7, V4- 59 variable heavy (VH)-
and still more variable  (VK)3-20 and VK3-15 light
(VL)-chain genes being the most represented [16-18].
These data suggest a model of antigen-driven origin for
these lymphoproliferative disorders with the recognition
of a limited number of HCV antigens [18,19].
The constrained heterogeneity of Ids shared by such
patients strongly suggests the possibility of targeting one
or few idiotypes to hit and eliminate the B cell clone
sustaining the HCV-associated NHL. One strategy is to
generate idiotype-specific MAbs to be employed in a
selective passive immunization [20]. An alternative strat-
egy is to use an idiotype vaccine [21] in order to elicit
an active humoral/cellular immune response as preven-
tive and/or therapeutic approach against the expansion
of the B cell clone sustaining the HCV-associated NHL.
We have previously shown that a multivariate and
multiparametric analysis can predict the innate and
early adaptive immune response induced by a vaccine
molecule in human monocyte-derived dendritic cells
(MDDCs) as well as whole peripheral blood mononuc-
lear cells (PBMCs) using an ex-vivo experimental
setting. This systems biology approach involves high-
throughput technologies such as global gene expression
profiling, multiplex analysis of cytokines and chemo-
kines, and multiparameter flow cytometry, combined
with computational modeling [22-26].
In the present study, we performed a multiparametric
analysis of the innate and early adaptive immune
response after ex vivo stimulation with the VK3-20 light
chain protein, the idiotype most frequently identified on
B cell clones sustaining the HCV-associated type II MC
and NHL. This objective has been pursued using freshly
isolated circulating human PBMCs.
Materials and methods
Enrolled subjects
Peripheral blood was obtained by venipuncture from 5
healthy volunteers and 10 HCV positive patients. All
human specimens were obtained and processed at the
National Cancer Institute in Naples under informed
consent, as approved by the Institutional Review Board.
Cell culture medium
PBMCs culture medium consisted of RPMI 1640 med-
ium (Life Technologies, Carlsbad, CA) supplemented
with 2 mM L-glutamine (Sigma), 10% fetal calf serum
(Life Technologies) and 2% penicillin/streptomycin
(5,000 I.U./5 mg per ml, MP Biomedicals).
MDDCs culture medium consisted of RPMI 1640
medium (Life Technologies, Carlsbad, CA) supplemen-
ted with 2 mM L-glutamine (Sigma), 1% non-essential
amino acids (Life Technologies), 1% sodium pyruvate
(Life Technologies), 50 μM 2-mercaptoethanol (Sigma)
and 50 μg of gentamicin (Life Technologies) per ml.
PBMC isolation and MDDC preparations
Fresh human PBMCs were isolated by Ficoll-Hypaque
density gradient centrifugation and plated in six-well
plates at a concentration of approximately 1 × 107
cells/well in a maximum volume of 3 ml/well for
induction. Alternatively, MDDCs were generated as
described previously [24,27], with minor modifications.
Briefly, isolated PBMCs were enriched for CD14+
monocytes by negative selection with a cocktail of
monoclonal antibodies (MAbs) from StemCell Tech-
nologies (Vancouver, British Columbia, Canada),
according to the instructions of the manufacturer.
Typically, greater than 80% of the cells were CD14+
after enrichment, as verified by flow cytometry. The
isolated monocytes were allowed to adhere to plastic
by plating in six-well plates at 1 × 106 cells per ml in
RPMI 1640 medium for 2 hrs. Adherent monocytes
were washed with RPMI 1640 medium and were then
cultured for 6 days in DC culture medium supplemen-
ted with 50 ng of recombinant granulocyte-macro-
phage colony-stimulating factor (rGM-CSF; R&D
Systems, Minneapolis, Minn.) per ml and 1,000 U of
recombinant interleukin-4 (rIL-4; R&D Systems, Min-
neapolis, Minn.) per ml.
Cell treatment
PBMCs or MDDCs were pulsed with serial dilutions of
the recombinant VK3-20 protein (15, 5 and 1.5 μg/ml)
provided by Areta International (Gerenzano, Italy)
(Patent PCT/IB2008/001936). In parallel, cells were
pulsed with 4 μg/ml of lipopolysaccharide (LPS), as
positive control. PBS was used as negative control. After
16-h incubation, PBMCs and MDDCs were harvested
and washed with 1× PBS (137 mM NaCl, 2.7 mM KCl,
10 mM Na2HPO4, 2 mM KH2PO4, pH 7.2) without
Calcium and Magnesium.
Flow cytometry
PBMCs and MDDCs were incubated for 30 min at 4°C
with human monoclonal antibodies specific for CD40,
CD80, CD83, CD86, HLA-DR, CD123, CD11c and
CD14 (BD Pharmingen, San Diego, CA), washed and
then analysed with a FACScalibur flow cytometer (BD
Pharmingen). Data analysis was carried out with
WinMDI2.8 Software.
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Multiplex cytokine analysis
At the time the cells were harvested, the supernatants
were also collected and stored frozen until analyzed.
Cytokine production was assessed using the BD™ Cyto-
metric Bead Array (CBA) tool (Becton Dickinson and
Company), according to the instructions of the
manufacturer. Data acquisition was performed using a
FACScalibur flow cytometer (BD Pharmingen), the ana-
lysis was performed with the BD CBA Analysis Software.
Statistical analyses
Intergroup comparisons were performed with the
Mann-Whitney U test (for univariate nonparametric
group analysis). All p-values were two-tailed and consid-
ered significant if less than 0.05.
Results
Clinical parameters of subjects included in the analysis
Fifteen subjects were enrolled in the study. Ten subjects
were HCV positive patients, of whom 2 were males and
8 were females (P1 - P10). Four of them were diagnosed
with NHLs and only one of them showed a type II MC
(Table 1). Five healthy subjects were enrolled as controls
(C1 - C5), matched for age and life style.
VK3-20 protein induces comparable maturation
phenotype in MDDCs and PBMCs of control subjects
Freshly derived PBMCs and immature MDDCs were
obtained from healthy HCV-negative subjects and were
incubated with 1.5 μg/ml, 5 μg/ml or 15 μg/ml of the VK3-
20 protein. After a 16-hr stimulation, the expression of sur-
face maturation/activation markers, such as CD40, CD80,
CD83, CD86 and HLA-DR was examined. The results
showed the up-regulation of all markers in PBMCs in
CD14+ monocyte population as well as CD123+
plasmacytoid DC (pDC) or CD11c+ myeloid DC (mDC)
(Fig. 1). Furthermore, MDDCs showed patterns of activa-
tion comparable to circulating mDCs and pDCs (Fig. 2).
Quantification of cells expressing activation markers in
the subsets of circulating monocytes, pDC and mDC
cells showed a trend of partial dose-response at increas-
ing concentrations of the VK3-20 protein, indicating a
specific activation/maturation activity on the circulating
antigen presenting cells (APCs) (Fig. 3). The expression
of CD40 and CD80 markers showed similar pattern of
induction (data not shown).
The similar levels of activation/maturation observed in
MDDCs and in PBMCs, regardless the marker of cell
population used for gating, confirmed the feasibility of
such analysis using “unselected” PBMCs, as previously
reported [22,25].
The VK3-20 protein induces maturation phenotype in
PBMC
Given the comparable results observed in MDDC and in
PBMC, subsequent analyses on samples from the
enrolled subjects were performed only on circulating
monocytes, pDC and mDC and the VK3-20-induced
expression of the markers was evaluated in terms of
mean fluorescence index (MFI).
The basal expression of the markers was largely
comparable between control and HCV+ subjects in the
considered cell populations (Fig. 4A to 4C). The only
exception is represented by basal CD83 expression,
which shows a trend of higher expression in the CD11c
+ mDC population of HCV+ subjects (Fig. 4A).
The stimulation with VK3-20 protein induces a trend
of increased expression of the activation/maturation
markers in all circulating cells, from control and HCV
seropositive subjects, although the most evident and
consistent pattern is observed in the CD123+ pDC and/
or CD11c+ mDC cells (Fig. 5 and 6A to 6C).
In particular, the lowest dose of VK3-20 used in the
experimental system (1.5 μg) appears to be already suffi-
cient to induce an increased expression of the activation
markers in cells from both groups of subjects.
In control subjects, VK3-20 induced the most evident
effect on the expression of CD86 in the circulating
monocytes, pDCs and mDCs(Fig. 5B). On the contrary,
the effect was significantly evident for all evaluated mar-
kers in the circulating cell populations from HCV +
subjects (Fig. 6A to 6C). This observation suggests that
overall the HCV seropositivity status does not signifi-
cantly affect the responsiveness to an immunogenic
stimulus (i.e., VK3-20) of circulating APC populations.
Cytokine production in VK3-20-loaded PBMCs
In order to evaluate the impact of the VK3-20 protein
stimulation on the production of cytokines involved in
Table 1 Clinical parameters of enrolled subjects
SEX HCV MC NHL
C1 M Neg Neg Neg
C2 M Neg Neg Neg
C3 F Neg Neg Neg
C4 F Neg Neg Neg
C5 F Neg Neg Neg
P1 F Pos Neg Neg
P2 M Pos Neg Neg
P3 F Pos Neg Neg
P4 M Pos Neg Neg
P5 F Pos Neg Neg
P6 F Pos n.d. Follicular
P7 F Pos n.d. Marginal
P8 F Pos n.d. Diffuse large B cell
P9 F Pos Pos Diffuse large B cell
P10 F Pos n.d. Neg
n.d. = not done.
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T-helper-cell activation, the levels of IL-2, gamma inter-
feron (IFN-g), tumor necrosis factor alpha (TNF-a),
IL-6, IL-4 and IL-10 were assessed in the supernatant of
PBMCs stimulated with the VK3-20 protein.
The average basal level of all evaluated cytokines
showed no significant difference between HCV positive
patients and control subjects (Fig. 7). Cell treatment
with the VK3-20 protein did not induce any increase in
the production of Th1 cytokines (IL-2 and IFN-g). On
the contrary, the VK3-20 protein induced a significantly
higher production of the Th2 cytokines (IL-4, IL-6, IL-
10, and TNF-a) in PBMCs from HCV seropositive and
control subjects, with the highest levels observed in the
samples treated with the highest concentration of VK3-
20 (15 μg) (p < 0.05) (Fig. 8 and 9). The levels of Th2
cytokines induced in the HCV+ samples were signifi-
cantly higher than those observed in control samples (p
< 0.01).
Discussion
The multivariate and multiparametric analysis described
in the present study shows that the basal and VK3-20-
induced expression of activation markers and co-stimu-
latory molecules in the evaluated circulating antigen
presenting cells (APCs), CD14+ monocyte as well as
CD123+ plasmacytoid DC (pDC) or CD11c+ myeloid
DC (mDC) populations, is largely comparable between
HCV-seropositive and control subjects. Overall, the
markers show a trend of increased expression in all cir-
culating cells, although the most evident and consistent
pattern is observed in the CD123+ pDC and/or CD11c+
mDC cells. No significant difference was observed
between results obtained in human monocyte-derived
dendritic cells (MDDCs) and circulating APCs, confirm-
ing previous results from us and other groups
[22,25,28,29].
The overall expression pattern suggests maturation/
activation induced by VK3-20, although for some speci-
fic markers and in some patients the trend does not
reach statistical significance. This observation suggests
that the HCV seropositivity status does not significantly
impair the immune activation status and the responsive-
ness of circulating APC populations to the VK3-20
immunogenic stimulus. Results obtained in parallel with
Figure 1 PBMCs were incubated with increasing doses of VK3-20 protein for 16 hrs. The expression of CD83, CD86 and HLADR was
analysed by FACScalibur flow cytometer in CD14+ monocytes, CD123+ pDCs and CD11c+ mDCs. Data analysis was carried out with WinMDI2.8
Software. One representative experiment is shown.
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lipopolysaccharide (LPS) used as a positive activation
factor, confirm the responsiveness of circulating APCs
from both groups analyzed in the present study. None-
theless, some HCV+ individuals show a complete lack of
maturation induced by VK3-20 in circulating APCs,
strongly suggesting the need for individual evaluations
to identify possible impairments in response to this
immunogen.
The present results confirm and extend data from
others showing a normal expression of surface mole-
cules involved in antigen-specific T-cell activation on
immature and mature DCs from HIV-1-infected and
hepatitis C virus (HCV)-HIV-coinfected individuals
[30-32]. Furthermore, monocyte-derived DCs from
either HCV-infected or HCV-HIV-coinfected subjects
have been previously shown to stimulate a mixed leuko-
cyte reaction in purified, allogeneic CD4+ T cells com-
parable to that with DCs derived from healthy donors
[33-35].
The average basal level of the Th2 (TNF-a, IL-6, IL-4,
and IL-10) cytokines is significantly higher (p < 0.02) in
HCV-seropositive compared to control subjects. On the
contrary, Th1 cytokine levels are equivalent in the two
groups. These results suggest a Th2 polarization
induced by an established HCV infection, as previously
extensively reported [36-39].
VK3-20 induced a significantly higher production of
the analysed Th2 cytokines in PBMCs from HCV-sero-
positive and control subjects, with the highest levels
observed in the samples treated with the highest con-
centration of VK3-20 (15 μg/ml) (p < 0.05). Further-
more, the levels of Th2 cytokines induced in the HCV+
samples were significantly higher than those identified
in the control samples (p < 0.01), suggesting the persis-
tence of a prevalent Th2 status. No increase in the pro-
duction of Th1 cytokines (IL-2 and IFN-g) was observed
(p < 0.4) in the control as well as HCV+ group. In parti-
cular, the production of IFN-g is known to be inhibited
by IL-10 [40], with a sequential detrimental effect on
the IL-12-mediated induction of IFN-g production by
NK and T cells [41-43]. Therefore, the high levels of
IL-10 and TNF-a induced by VK3-20 could explain the
lack of increased production of IFN-g in both groups.
The observed discrepancy between the VK3-20 concen-
tration necessary for the maximal induction of activation
markers (1.5 μg/ml) and the one necessary for the
Figure 2 Comparative analysis of the expression of surface maturation/activation markers (CD83, CD86, HLADR) performed on
stimulated MDDCs, CD123+ pDCs and CD11c+ mDCs.
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Figure 3 6-color flow cytometric analysis was performed on VK3-20 protein-stimulated monocytes, mDC/pDC cell populations and
immunophenotype analysis of surface maturation/activation marker expression is shown. Values in each quadrant represent the
percentage of positive cells.
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Figure 4 Basal level expression of surface maturation/activation markers, indicated as Mean Fluorescence Index (MFI), on PBMC-
derived monocytes and DC from control and HCV positive (HCV+) subjects. CD14 = CD14+ monocytes; CD123 = CD123+ pDCs; CD11c =
CD11c+ mDCs.
Figure 5 Expression of surface maturation/activation markers, indicated as Mean Fluorescence Index (MFI), induced by the indicated
concentrations of VK3-20 and LPS in PBMC-derived monocytes and DC from control subjects. CD14 = CD14+ monocytes; CD123 =
CD123+ pDC; CD11c = CD11c+ mDC.
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Figure 6 Expression of surface maturation/activation markers, indicated as Mean Fluorescence Index (MFI), induced by the indicated
concentrations of VK3-20 and LPS in PBMC-derived monocytes and DC from HCV seropositive subjects. CD14 = CD14+ monocytes;
CD123 = CD123+ pDC; CD11c = CD11c+ mDC.
Figure 7 Analysis of basal level production of Th1 and Th2 cytokines in supernatants of PBMCs from control and HCV positive (HCV+)
subjects.
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Figure 8 Analysis of Th1 and Th2 cytokines in supernatants of PBMCs from control subjects induced by the indicated concentrations
of VK3-20 and LPS.
Figure 9 Analysis of Th1 and Th2 cytokines in supernatants of PBMCs from HCV seropositive subjects induced by the indicated
concentrations of VK3-20 and LPS.
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maximal induction of cytokine expression (15 μg/ml)
may suggest a different pathway of activation involved
in the two independent biological effects, which need
further investigation.
The similar response observed in HCV-seropositive
subjects, regardless of the diagnosis of type II MC or
NHL, would suggest the absence of an in vivo priming
for the VK3-20. In this regard, the expression of VK3-20
in the clonal B-cell populations of these subjects is cur-
rently under evaluation.
The impairment of basal and antigen-induced produc-
tion of Th1-polarizing cytokines for HCV-seropositive
individuals is in concordance with our previous observa-
tions on PBMCs from HIV infected subjects exposed ex
vivo to a VLP-based HIV vaccine model [25,44].
The overall results here described represent a proof-
of-concept and confirm the possibility of screening
donor susceptibility to an antigen treatment using circu-
lating APCs, CD14+ monocytes as well as CD123+ plas-
macytoid DC (pDC) or CD11c+ myeloid DC (mDC)
populations, without the need of purification and ex
vivo selection of DCs, simplifying the identification of
“responsive” vaccinees and providing mechanisms of
eventual failures in individuals enrolled in clinical trials.
When necessary, additional and more detailed studies
on fractionated cell types would allow identification and
a better characterization of the individual cells involved
in mediating the in vivo response. In conclusion, our
results indicate that circulating APCs from HCV-sero-
positive patients can be functional in active autologous
immunotherapy strategies. In particular, the results
strongly suggest the induction of the innate and early
adaptive immune response by the protein corresponding
to the VK3-20 light chain of the idiotype most fre-
quently identified on B cell clones sustaining the HCV-
associated type II MC and NHL. Therefore, its use as
preventive as well as therapeutic vaccination strategy
appears to be feasible and potentially effective. However,
specific Th1-driving adjuvant strategies might be neces-
sary to obtain the sought efficient therapeutic effect.
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Translating Tumor Antigens into Cancer Vaccines
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Vaccines represent a strategic successful tool used to prevent or contain diseases with high morbidity and/or
mortality. However, while vaccines have proven to be effective in combating pathogenic microorganisms, based
on the immune recognition of these foreign antigens, vaccines aimed at inducing effective antitumor activity are
still unsatisfactory. Nevertheless, the effectiveness of the two licensed cancer-preventive vaccines targeting
tumor-associated viral agents (anti-HBV [hepatitis B virus], to prevent HBV-associated hepatocellular carci-
noma, and anti-HPV [human papillomavirus], to prevent HPV-associated cervical carcinoma), along with the
recent FDA approval of sipuleucel-T (for the therapeutic treatment of prostate cancer), represents a significant
advancement in the field of cancer vaccines and a boost for new studies in the field. Specific active immuno-
therapies based on anticancer vaccines represent, indeed, a field in continuous evolution and expansion.
Significant improvements may result from the selection of the appropriate tumor-specific target antigen (to
overcome the peripheral immune tolerance) and/or the development of immunization strategies effective at
inducing a protective immune response. This review aims to describe the vast spectrum of tumor antigens and
strategies to develop cancer vaccines.
CANCER IMMUNOTHERAPY
Cancer immunotherapy may be classified into passive as well
as active strategies, with the latter being specific or nonspecific
(117). Passive or “adoptive” immunotherapy is based on ad-
ministration of antitumor antibodies or transfer of tumor-re-
active lymphocytes. Active immunotherapy is aimed either at
eliciting a specific de novo host immune response against se-
lected tumor antigens (Ags) by employing cancer vaccines or at
amplifying the existing antitumor immune response by admin-
istering nonspecific proinflammatory molecules or adjuvants.
In this context, considering the disappointing results up to now,
the quest for specific and selective tumor antigens for devel-
oping tumor-specific cancer vaccines, optimal delivery systems
(i.e., dendritic cell [DC]-based vaccines), adjuvants, and strat-
egies to overcome immune tolerance and regulatory T (Treg)
cell responses is the main goal for several research groups and
leading health care companies.
QUEST FOR THE APPROPRIATE TUMOR ANTIGEN
The role of the immune system in tumor containment and/or
“rejection” has been studied for decades, showing the possi-
bility of inducing an immune response able to reject an exper-
imentally transplanted tumor. However, the “immunosurveil-
lance of tumors” theory independently postulated by Burnet
(19–21) and Thomas (173) has not held the original promise,
and much skepticism has been raised by different authors.
More recently, the original concept of immunosurveillance has
been further elaborated by Schreiber et al. (53, 54) into the
“cancer immunoediting” hypothesis, which postulates three
main phases: elimination, equilibrium, and escape. In particu-
lar, in the elimination phase, cells of the innate and adaptive
immune responses may eradicate the developing tumor and
protect the host from tumor formation. If the elimination pro-
cess is not successful, the tumor cells may enter the equilibrium
phase and be immunologically shaped by immune “editors” to
produce new populations of tumor variants. These variants
may eventually evade the immune system and become clini-
cally detectable in the escape phase (53, 54).
The cells playing a key role in this process have been iden-
tified in both the innate (e.g., natural killer cells, natural killer
T cells, macrophages, and dendritic cells) and the adaptive
(e.g., CD4 Th1 and CD8 T cells) immune systems, whose
final goal is to kill the antigen-bearing tumor cells. More re-
cently, a relevant role for an additional subset of CD4 T
helper cells (named Th17) in the immune response to cancer
has been proposed and described by several authors (reviewed
in reference 203).
However, different approaches have failed to induce an ef-
fective antitumor immune response, suggesting the notion of
“nonimmunogenicity” of tumors (69). However, more recently
it has been shown that the low tumor immunogenicity is not
due to the lack of target “tumor” antigens but to their inability
to induce an effective immune response. Among several pos-
sible biological reasons, this would be consequent to the
growth of tumors in the absence of an inflammation process
necessary to establish the tissue microenvironment essential to
* Corresponding author. Mailing address: Laboratory of Molecular
Biology and Viral Oncogenesis & AIDS Reference Center, Istituto
Nazionale Tumori “Fondazione G. Pascale,” Via Mariano Semmola 1,
80131 Naples, Italy. Phone: 39-081-5903273. Fax: 39-081-5451276. E-
mail: irccsvir@unina.it.
 Published ahead of print on 3 November 2010.
23
recruit and induce activation and maturation of the antigen-
presenting cells (APCs), which represent the key point of ini-
tiating an effective adaptive humoral and cellular immune re-
sponse.
In this perspective, the search for human tumor antigens as
potential targets for cancer immunotherapy has led to the
discovery of several molecules expressed mainly or selectively
on cancer cells.
Antigens used in cancer vaccines, indeed, should preferably
be molecules differently expressed on normal and tumor cells;
however, most antigens are derived from mutated or modified
self-proteins, which may induce immune tolerance (61). This
aspect represents a challenge for the appropriate design of
vaccines that have to overcome such tolerance in order to elicit
specific antitumor immunity without “undesired” autoimmu-
nity side effects (130).
MULTIPLE “UNDEFINED” ANTIGENS
It is well known that tumors show the accumulation of sev-
eral genetic modifications in somatic cells (63, 186), which
provide cancer cells with the selective growth advantage to
initiate clonal expansion (66).
In this context, cancer genes have been originally studied
based on their possible relation to cancer (59). More recently,
high-throughput technologies have enabled the identification
of mutated genes in cancers without any hypothesis-driven
bias, whose number has resulted to be surprisingly high, with a
functional heterogeneity broader than previously thought (140,
169). These studies have been performed in breast, colorectal,
pancreatic, and lung cancers and glioblastoma and, overall,
have identified almost 400 candidate cancer genes (CAN-
genes) (48, 83, 134, 199). Interestingly, systems-level analyses
show that, despite the low degree of overlap in terms of gene
identity, cancer signatures converge on specific biological pro-
cesses, as defined by significant molecular and functional as-
sociations between genes and/or proteins (68, 163, 170).
Considering the high number of potential tumor antigens for
each individual type of cancer, the concept of immunizing with
whole tumor cells to avoid the exclusion of potentially relevant
antigens from the vaccine is still valid. A further advantage is
that since whole tumor cells express an array of antigens, this
vaccine approach circumvents the major histocompatibility
complex (MHC) restriction and the need for specific patient-
tailored epitope identification. The efficacy of autologous tu-
mor cells as a cancer vaccine has been tested in several clinical
trials targeting different tumor types, including colorectal can-
cer (67, 185) and melanoma (3, 12). Alternatively, to overcome
the limitations of patient-tailored vaccines (e.g., standardiza-
tion of large-scale production, variability in the quality and
composition of the vaccines, and lack of reliable comparative
analysis of clinical outcome), the use of allogeneic tumor cell
lines as cancer vaccines has been tested for prostate cancer
(114, 160, 162).
However, the effectiveness of such a vaccine strategy is
dramatically hampered by the immune system’s inherent
tolerance to several tumor antigens, as they may be ex-
pressed by normal tissues or presented to T cells in a non-
stimulatory context. As a consequence, the breaking of tol-
erance and the containment of immune suppression need a
potent and specific immune stimulus combining antigens
and immunological adjuvants (reviewed in references 32 and
192). Whole tumor cell vaccines can be made more immu-
nogenic by modifying tumor cells to express costimulatory
molecules and/or cytokines, such as granulocyte-macro-
phage colony-stimulating factor (GM-CSF), which has
proven to be more effective than others in inducing recruit-
ment, maturation, and function of dendritic cells (DCs), the
most potent type of antigen-presenting cell (APC) (50, 57,
81).
In particular, vaccination with genetically engineered, irra-
diated melanoma cells, modified to secrete GM-CSF, was
shown to improve tumor antigen presentation through in-
creased DC and macrophage recruitment, enabling the gener-
ation of effective melanoma-specific CD4 and CD8 T cells,
CD1-restricted NKT cells, and antibodies (51, 57). Although
the advantages of using GM-CSF as an adjuvant for cancer
vaccines have been reported, recent observations have sug-
gested the potential of GM-CSF to induce immune suppres-
sion, which may negatively impact the management of cancer
patients (reviewed in reference 34). Whole tumor cell vaccines
expressing high levels of costimulatory molecules are currently
being pursued to treat aggressive cancers such as acute myeloid
leukemia (AML) (26, 31).
Another approach based on multiple “undefined” antigens
takes into account the heat shock proteins (HSPs), which are
ubiquitous, intracellular molecular protein chaperons whose
expression increases under conditions of elevated tempera-
tures and metabolic stress (105) to enhance the antigen pro-
cessing and presentation by MHC molecules (167). Conse-
quently, HSPs are associated with a large repository of
peptides consisting of self-peptides as well as the entire anti-
genic peptide repertoire of cancer cells. Therefore, the cross-
presentation and cross-priming of tumor antigens mediated by
HSPs may result in a valid strategy, especially when the
amount of antigen is a limiting factor (reviewed in references
15 and 119). Heat shock protein-based vaccines have been
shown to be effective in mice when the HSP was purified from
tumor cells matching the implanted tumor (166, 171, 179).
Vaccines based on proteins complexed with HSPs, purified
from autologous tumors (HSP-protein complex), have been
evaluated in clinical trials targeting different cancers. In par-
ticular, the immunogenicity and efficacy of HSP-protein com-
plex 96 (HSPPC-96; vitespen) made of tumor peptides associ-
ated with the heat shock protein gp96 has been extensively
assessed in preclinical and clinical trials for a wide range of
cancers, including phase I and II trials in colorectal cancer
(110), melanoma (7, 138), and renal cell carcinoma (82) and
two phase III studies of melanoma and renal cell carcinoma
(165, 172, 197, 198). Furthermore, a full-length human papil-
lomavirus type 16 (HPV16) E7 antigen fused to HSP65 from
Mycobacterium bovis BCG (HspE7) (33) has been evaluated in
a phase II clinical trial, resulting in lesion regression in women
with grade III cervical intraepithelial neoplasia (CIN III) (55,
183).
DEFINED ANTIGENS
Cancer vaccines based on defined specific tumor antigens
should elicit a very specific effector and memory cell response
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with a limited chance of inducing autoimmunity. Such an ap-
proach may have opposite biological effects. One effect is the
possible undesired selection and expansion of tumor variants
which lack the target tumor antigen and are biologically resis-
tant to the vaccine-induced immune response. Such tumor
variants, however, may in turn induce a beneficial effect, broad-
ening the immune response against newly expressed antigens
not present in the original vaccine in a process defined
“epitope spreading” (23, 144).
Since the identification of MAGE-1, the first gene re-
ported to encode a human tumor antigen recognized by T
cells (182), a large number of tumor antigens have been
described (Table 1). Initial classification was based on ex-
pression profiles, with tumor-specific antigens (TSAs) being
expressed only by cancer cells and tumor-associated anti-
gens (TAAs) representing the mutated counterparts of pro-
teins expressed by normal tissues. The currently accepted
classification, however, includes only TAAs, which are di-
vided into shared and unique TAAs and further classified
into class I and class II HLA-restricted TAAs, according to
the HLA allele restriction (reviewed in reference 125).
Among the shared TAAs, the following three main groups
can be identified: (i) cancer-testis (CT) antigens, (ii) differen-
tiation antigens, and (iii) widely occurring, overexpressed an-
tigens.
Among shared tumor-specific antigens, cancer-testis (CT)
antigens are expressed in histologically different human tumors
and, among normal tissues, in spermatocytes/spermatogonia of
the testis and, occasionally, in placenta. CT antigens result
from the reactivation of genes which are normally silent in
adult tissues (46) but are transcriptionally activated in different
tumor histotypes (45). Many CT antigens have been identified
and used in clinical trials, although little is known about their
specific functions, especially with regard to malignant transfor-
mation. This group of TAAs includes MAGE-A1 (30, 177),
NY-ESO-1 (78), and SSX-2 (1).
Differentiation antigens are shared between tumors and the
normal tissue of origin and found mostly in melanomas and
normal melanocytes (Gp100, Melan-A/Mart-1, and Tyrosi-
nase) (4, 89–91, 131, 190), although they are also found in
epithelial tissues and tumors such as prostate tumors (prostate-
specific antigen [PSA]) (37, 38) and breast carcinomas (mam-
maglobin-A) (79). Moreover, expression of several oncofetal
antigens appears to be increased in many adult cancer tissues,
including carcinoembryonic antigen (CEA), which is highly
expressed in colon cancer (178). TAAs from this group, despite
TABLE 1. List of most relevant TAAs recognized by T cellsa
a References for antigens listed here are reported in the text. N/A, not applicable.
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representing self-antigens, have been and still are commonly
used in current cancer vaccination trials, often together with
CT antigens.
Widely occurring, overexpressed TAAs have been detected
in different types of tumors as well as in many normal tissues,
and their overexpression in tumor cells can reach the threshold
for T cell recognition, breaking the immunological tolerance
and triggering an anticancer response. Among the most inter-
esting TAAs of this group are the antiapoptotic proteins (livin
and survivin) (154, 155), hTERT (116, 187, 188), and tumor
suppressor proteins (e.g., p53) (2, 180).
Unique TAAs, on the other hand, are products of random
somatic point mutations induced by physical or chemical car-
cinogens and therefore expressed uniquely by individual tu-
mors and not by any normal tissue, representing the only true
tumor-specific antigens (Ags) (reviewed in reference 133).
Such Ags characterize each single neoplasm and were shown to
be diverse between tumors induced in the same animal or even
in different tissue fragments from the same tumor nodule (61,
141, 200). A relevant feature of unique Ags is their potential
resistance to immunoselection if the mutated protein is crucial
to the oncogenic process and thus indispensable for maintain-
ing the neoplastic state. As a consequence, unique Ags should
elicit an immune response clinically more effective than that of
shared Ags. However, identification of unique tumor antigens
for solid human tumors requires sequencing of the whole ge-
nome of each individual tumor in order to identify mutated
genes and select peptides whose motifs are predicted to be
presented by the patient’s HLA alleles. Moreover, each tumor
bears highly heterogeneous sets of defects in dozens of differ-
ent genes (25, 83, 85, 142, 199) which need to be further
verified for their substantial contribution to the tumor devel-
opment and progression and, consequently, for their relevance
as vaccine targets (58).
On the contrary, unlike for the solid tumors, the strategy of
identifying unique TAAs is relatively easy and feasible for
tumors of hematological origin, such as B cell lymphomas, for
which the target antigen is well known, being represented by
the immunoglobulin idiotype (Ig Id) included in the B cell
receptor (BCR). Therefore, sequencing analysis for the iden-
tification of cancer-related mutations can be selectively fo-
cused on the Ig Id, which can be used for developing a patient-
specific vaccine (8, 168). More recently, however, it has been
demonstrated that the BCR repertoire expressed by clonal B
cells sustaining hepatitis C virus (HCV)-associated non-
Hodgkin’s lymphoma (NHL) is not random, with a restricted
representation of immunoglobulin idiotypes in different pa-
tients (28, 43, 137). As a consequence, it is possible to over-
come the limitations of tailor-made individual vaccines by de-
signing shared idiotype vaccines to elicit immunity, targeting
the B cell clone sustaining the HCV-associated NHL in a
broad spectrum of patients (18, 44).
An additional class of tumor antigens is represented by tu-
mor-associated carbohydrate antigens (TACAs), which are gly-
cans uniquely or excessively expressed on the cancer cell sur-
face (143) and correlate with various stages of cancer
development (42, 65). However, TACAs do not elicit T cell
responses and are usually poorly immunogenic given their
structural similarity to normal antigens (80). Nevertheless,
conjugation to a carrier protein increases their immunogenic-
ity, enhancing the presentation of carbohydrate antigens to
antigen-presenting cells as well as induction of helper T cell
activation (92, 106). In particular, keyhole limpet hemocyanin
(KLH) has been shown to be the most effective carrier for
TACAs (86), and KLH conjugates of GM2 for melanoma (27)
as well as those of sTn for breast cancer (73) have both entered
phase III clinical trials. However, the disappointing outcomes
of these vaccine clinical trials, in terms of time-to-disease pro-
gression and overall survival, have driven the generation of
several forms of fully synthetic carbohydrate vaccines, which
have been shown to be immunogenic regardless of the use of a
protein carrier or external adjuvant (6, 13, 22, 76, 176, 194).
Unfortunately, despite all efforts, TACA-based cancer vac-
cines have failed to induce sufficient T cell-mediated immune
responses in cancer patients, and none has been approved for
clinical use yet (64).
APPLICATION OF DEFINED ANTIGENS AS
CANCER VACCINES
Most cancer vaccine clinical trials have been performed with
peptide-based vaccines, employing either cancer-testis anti-
gens or differentiation TAAs, and despite the induction of a
high frequency of specific T cells, the clinical outcomes have
been disappointingly limited (29, 132, 136, 148, 149) (Table 2).
There are many possible reasons for these unsatisfactory re-
sults, including immune tolerance induced by shared TAAs
(35, 112) and limited cytotoxic T lymphocyte (CTL) expansion
due to activation of regulatory T lymphocytes (122). Further-
more, single peptides elicit a CD8 T cell response with a
narrow epitope specificity, which may result in limited immu-
nological efficacy and in the induction of immune escape mech-
anisms (146).
Several strategies have been adopted to overcome such lim-
itations, including the introduction of inflammatory cytokines
in the vaccination protocol, such as alpha interferon (IFN-)
(94, 135) and interleukin-2 (IL-2) (104, 147, 150, 151), with
conflicting results. An alternative strategy is to generate pep-
tide variants of TAAs (47, 72, 84), including mimotopes, het-
eroclitic peptides, altered-peptide ligands, and superagonists,
introducing MHC-anchor residue modifications (127, 181),
systematic residue substitutions (161), combinatorial peptide
libraries (111, 139), and genetically encoded peptide libraries
(39, 191). However, considering the overall disappointing re-
sults of clinical trials testing such peptide variants, additional
strategies have been developed to broaden the repertoire of
responding T cells by introducing amino acid substitutions in
the peptide-MHC binding surface (16, 74, 102).
Significant improvement in the immunogenicity of single-
peptide vaccines has been achieved using long peptides deriv-
ing either from the chemical linkage of multiple immunogenic
epitopes (71, 159) or from naturally occurring linked CTL and
Th epitopes, as shown for human papillomavirus (HPV) E6-E7
proteins (93, 193), the CT antigen NY-ESO-1 (202), and HER-
2/neu (49, 95). The enhanced immunological potency of long
peptides, which do not bind directly to MHC class I molecules
as 8-mer to 10-mer CTL epitopes do, is most likely due to their
efficient presentation to CTL precursors through processing by
DCs (9, 14, 113, 156), which should dramatically reduce tran-
sient CTL responses or tolerance (174, 175). Furthermore,
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long peptides may persist longer in inflamed lymph nodes in
close proximity to the vaccination site, resulting in the clonal
expansion of IFN--producing effector T cells and improved
antitumor CTL response (14). Finally, the presence of multiple
immunogenic epitopes in long peptides would ensure the in-
teraction with different HLA class I and class II alleles, elicit-
ing a broad T cell response against many epitopes, including
the immunodominant ones, and reducing the emergence of
tumor escape variants.
DENDRITIC CELLS AS AN ANTIGEN
DELIVERY SYSTEM
An effective vaccine needs to efficiently hit the innate im-
mune system and, downstream, the adaptive humoral and cel-
lular immunity to elicit an adequate level of effector cells and
establish the immunological memory. To this aim, vaccine
strategies effective in activating both innate and adaptive im-
munity are actively pursued by several groups, and among the
different possible strategies, dendritic cell (DC)-based vaccines
represent one of the most promising strategies (reviewed in
references 96 and 126).
Dendritic cells can be generated in vitro from CD34 pro-
genitor cells derived from the patient’s bone marrow or pe-
ripheral blood, and maturation can be obtained ex vivo with a
cocktail of several cytokines.
The original protocol for DC generation has been designed,
including GM-CSF and IL-4 (121, 157), but it has been shown
that functionally distinct DC subsets can be generated by using
different cytokines. Indeed, activated monocytes induced with
IFN-/, thymic stroma lymphopoietin (TSLP), tumor necro-
sis factor (TNF), or IL-15 will differentiate into IFN DCs,
TSLP DCs, TNF DCs, or IL-15 DCs, respectively, able to
induce different types of immune responses (5). For example,
melanoma-peptide-pulsed IL-15 DCs are much more efficient
than IL-4 DCs in inducing antigen-specific CTL differentiation
in vitro (52), whereas IFN- DCs show improved activation of
T helper cells (128). Similarly, different DC maturation path-
ways may significantly impact their capacity to elicit T cell
immunity (99). Indeed, GM-CSF/IL-4 DCs activated with a
cocktail of IFN-, poly(I:C), IL-1, TNF, and IFN- are much
more effective in inducing specific CTLs than “gold standard”
DCs matured with a cocktail of macrophage cytokines, includ-
ing IL-1/TNF/IL-6/prostaglandin E2 (PGE2) (109). More-
over, PGE2 can skew the differentiation of T helper cells to
Th2 cells, blocking the production of IL-12 p70 (87, 88).
Matured DCs are then loaded with tumor antigens as pep-
tides (24), tumor lysates (121), or apoptotic debris (129), which
are processed and presented on the DC surface in the context
of MHC class I and II molecules. The matured and antigen-
loaded DCs are then transferred back to the patients for the
generation of an antitumor immune response (reviewed in
references 5 and 157) (Fig. 1).
Concerning the strategy of using tumor lysates or apoptotic
debris as source of tumor antigens, the original and standard
procedure is to use autologous DCs loaded with autologous
tumor cells, both derived from the treated patient. However,
the preparation of sufficient amounts of autologous tumor cells
might be a significant limiting factor, and to overcome this
hurdle, the use of allogeneic tumor cell lines as sources of
tumor antigens has been proposed. Tumor cell lines, indeed,
share many TAAs with the patients’ autologous tumor cells
and can be efficiently expanded in vitro. Cellular fusions gen-
erated by autologous DCs and allogeneic tumor cell lines have
been shown to induce antigen-specific polyclonal CTLs, with
cytotoxic activity against autologous tumor cells (10, 97, 98). A
further possible alternative is to use allogeneic DCs from
healthy donors as a fusion partner, given that unprimed T cells
from an individual react against the foreign MHC antigens of
another individual. It has been demonstrated, indeed, that
fusions of both autologous and allogeneic DCs are effective in
inducing antitumor immunity in humans (62), although this
approach can be applied only in selected situations (reviewed
in reference 96).
The effectiveness of DC-based vaccines has been demon-
strated in specific tumor stages, and very recently, the first
autologous cellular immunotherapy has received FDA ap-
proval for the treatment of asymptomatic or minimally
symptomatic metastatic hormone-refractory prostate cancer
(HRPC). Sipuleucel-T consists of autologous PBMCs
loaded with recombinant human prostatic acid phosphatase
(PAP) linked to granulocyte-macrophage colony-stimulat-
TABLE 2. Peptide-based cancer vaccine clinical trials for most representative tumorsa
a Further information on current cancer vaccine clinical trials is available at www.clinicaltrials.gov. N.  number of
total clinical trials registered for the corresponding tumors.
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ing factor (PAP–GM-CSF), which has proven to be effective
in phase III clinical trials (70).
However, results from multiple clinical trials with DC-based
cancer vaccines have been contradictory, and only fractions of
the enrolled patients show potent antitumor immune re-
sponses (reviewed in references 96 and 103). Several reasons
may account for this modest clinical outcome, including the
reproducible efficiency of DC generation and the possible in-
duction of adaptive CD4 CD25 Foxp3 regulatory T (Treg)
cells in the presence of transforming growth factor  (TGF-)
or IL-10 derived from the tumor microenvironment (189).
HARNESSING IMMUNE TOLERANCE AND Treg CELLS
Naturally occurring regulatory T (Treg) cells account for 5%
to 10% of peripheral CD4 T cells (60, 152), whose key role is
to inhibit self-reactive effector T cells, inducing peripheral T
cell tolerance (152). Moreover, Treg cells have been found to
be increased in peripheral blood and tumors in a variety of
human cancers (75, 107, 196), resulting in poorer prognosis
and reduced survival (153, 158, 195, 201). The presence of an
increased percentage of circulating Treg cells may, indeed,
represent a major obstacle to the success of cancer vaccines,
and partial depletion of Treg cells has been shown to enhance
DC vaccine-induced immune responses in cancer patients (41,
123). In this perspective, cancer vaccines may be more effective
when combined with therapeutic interventions aimed at elim-
inating and/or controlling naturally occurring CD4 CD25
regulatory T cells. Studies done in the 1980s showed that pre-
treatment with cytostatic drugs (i.e., cyclophosphamide) was
significantly enhancing the efficacy of adoptive cancer immu-
notherapy in preclinical (124) as well as clinical (11) settings.
Several clinical trials are currently ongoing to assess the effi-
cacy of cyclophosphamide to control Treg cells and improve
the immune response to cancer vaccines in humans (56). Al-
ternative strategies to eliminate and/or control naturally occur-
ring Treg cells are represented by the use of a recombinant
IL-2 diphtheria toxin conjugate (Ontak), which has been
shown to enhance tumor-specific T cell responses to vaccines
(41, 118) as well as to improve immune responses in patients
with metastatic melanoma (108).
Furthermore, depletion of CD4 CD25 Treg cells may also
be achieved using an anti-CD25 monoclonal antibody (MAb),
as shown for melanoma or breast cancer vaccine (77, 115, 145).
The role of Toll-like receptor (TLR) agonists as inhibitors of
Treg cell function (36, 184) is still controversial. It has been
reported, indeed, that different TLR agonists can be effective
in limiting tumor progression when used as adjuvants to coad-
ministered a cancer vaccine (120, 164) or as stand-alone im-
munotherapeutics, eliciting an immune response to tumor self-
antigens (17, 100, 101). Nevertheless, such effects are not
FIG. 1. Schematic representation of a DC-based vaccine preparation. CD14 monocytes or CD34 hematopoietic progenitors are derived from
patients. Different DC subsets are generated in vitro, with distinct specialization in driving adaptive immunity to the Th1 or Th2 response. Mature
DCs are loaded with one of the indicated sources of tumor antigens and reinfused in the patient. The most relevant cell markers characterizing
the different activation stages of DCs are indicated.
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univocal, given that TLR agonists may induce differentiation,
proliferation, or activation of Treg cells. Human CD4 CD25
Treg cells stimulated with the TLR5 agonist flagellin, indeed,
show enhanced expression of Foxp3 and increased suppressive
function (40).
CONCLUSIONS AND FUTURE DIRECTIONS
The cancer vaccine field is constantly growing and generat-
ing a considerable amount of information in terms of antigen
target identification and delivery as well as immune modula-
tion, which will represent the knowledge platform to accom-
plish the ultimate aim of developing an effective cancer vac-
cine. However, large-scale clinical trials of current strategies
and protocols have not yet proved to be as efficacious as
needed for complete tumor regression.
Several reasons may account for these disappointing results,
including (i) tumor evasion from immune recognition, (ii) in-
efficient induction of high-affinity adaptive immunity, and (iii)
tumor-induced immunosuppression. Each of these aspects
needs to be addressed and possibly solved in order to increase
the chances of success.
In this discovery process, the systems biology approach can
have a great impact not only on the comprehension of multiple
pathways involved in tumor development and progression but
also on the dissection of molecular mechanisms involved in the
efficient induction of effective innate and adaptive immunity.
Such an approach, ultimately, will have a significant impact on
cancer vaccine development for the identification of both novel
potential target antigens and molecular prediction markers of
immunogenicity.
This would represent the real switch from the “empirical” to
the “knowledge-based” age of cancer vaccinology, enabling the
development of strategies with enhanced therapeutic efficacy
to significantly improve the quality of life of cancer patients.
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Dendritic cells in the pathogenesis and treatment of 
human diseases: a Janus Bifrons?
The main function of immune system is to pro-
tect our body from invading foreign pathogens 
or newly generated expanding cells (i.e., cancer 
cells) by neutralizing cell-free microorganisms 
or killing targeted cells. To efficiently fulfill its 
function, the immune system must distinguish 
self from nonself antigens in order to minimize 
collateral immunopathological consequences, 
which may possibly lead to a wide repertoire of 
autoimmune diseases. 
In this respect, dendritic cells (DCs) per-
form an important function in the generation 
and regulation of immunity [1]. They circulate 
throughout the body and constantly sense the 
surrounding environment for invading path-
ogens, malignant cells or other inf lamma-
tory signals. This sentinel function of DCs, 
as well as the expression of several immune-
modulating molecules, makes DCs unique in 
their capacity to stimulate naive T cells and 
shape the T-cell immune response into dif-
ferent effector T-cell subsets. This function is 
mediated by pathogen recognition receptors 
(PRRs) that detect foreign antigens (i.e., patho-
gen-associated molecular patterns [PAMPs]); 
activating specific signaling pathways to drive 
biological and immunological responses [2,3]. 
Among the PRRs, Toll-like receptors (TLRs) 
are widely expressed on innate immune cells 
(including DCs, macrophages, mast cells and 
neutrophils), endothelial cells and fibroblasts, 
and their expression is regulated in response 
to several factors, including foreign antigens, 
vaccines and cytokines [4–7].
In addition to TLRs, other important fami-
lies of PRRs are plasma-membrane and cyto-
plasmic receptors, including the C-type lectins; 
which recognize a range of microbial stimuli 
from pathogens such as HIV, hepatitis C virus, 
Helicobacter pylori, and Mycobacterium tubercu‑
losis [8,9], and NOD receptors; which recognize 
components of intracellular bacteria [10]. In addi-
tion, DCs express a wide variety of receptors for 
inflammatory mediators that are released upon 
damage. As an example, some malignant cells 
express so-called damage-associated molecular 
patterns such as heat-shock proteins [11], uric 
acid [12] and high mobility group box 1 [13].
Once DCs have captured a foreign nonself 
antigen, they undergo a complex maturation pro-
cess, remodeling from ‘antigen-capturing’ into 
‘antigen-presenting’ cells. Indeed, they display 
foreign antigens complexed with MHCs on their 
surface, to enable recognition of the antigen by 
T cells through their T-cell receptor. This inter-
action, which is also referred to as signal 1, is 
an essential step to drive the adaptive immune 
response. However, in the absence of a second 
‘costimulation’ signal, signal 1 is insufficient to 
activate naive T cells and will result in T-cell 
anergy or deletion [14–16]. Costimulatory mole-
cules for signal 2, such as CD80 and CD86, can 
Dendritic cells (DCs) represent the bridging cell compartment between a variety of nonself antigens 
(i.e., microbial, cancer and vaccine antigens) and adaptive immunity, orchestrating the quality and potency 
of downstream immune responses. Because of the central role of DCs in the generation and regulation 
of immunity, the modulation of DC function in order to shape immune responses is gaining momentum. 
In this respect, recent advances in understanding DC biology, as well as the required molecular signals 
for induction of T-cell immunity, have spurred many experimental strategies to use DCs for therapeutic 
immunological approaches for infections and cancer. However, when DCs lose control over such ‘protective’ 
responses – by alterations in their number, phenotype and/or function – undesired effects leading to 
allergy and autoimmune clinical manifestations may occur. Novel therapeutic approaches have been 
designed and currently evaluated in order to address DCs and silence these immunopathological processes. 
In this article we present recent concepts of DC biology and some medical implications in view of 
therapeutic opportunities.
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either amplify or regulate the interaction between 
DCs and T cells. Finally, DCs can polarize naive 
T cells into Th1, Th2, Th17 or regulatory T 
(Treg) cell through the necessary third signal; 
provided by the secretion of cytokines such as 
IL-12, IL-23 or IL-10, as well as the expression 
of surface molecules, such as OX40-L or ICOS-1 
(Figure 1) [17–20]. From the insights above, it is evi-
dent that alterations in the number, phenotype 
and/or function of DCs have been implicated in 
various human inflammatory and autoimmune 
immunopathological diseases [21,22]. 
Considering the key role of DCs in the activa-
tion and polarization of T cells in the response to 
external (i.e., microbial) and internal (i.e., can-
cer cells) nonself antigens, their manipulation 
for therapeutic approaches is evaluated in many 
diseases. During the past decade, progress has 
been made with regard to cellular therapies that 
have been designed to elicit or amplify immune 
responses. DC-based activation immunothera-
pies, so-called ‘positive’ vaccinations, have been 
widely used for cancer [23,24] and infectious dis-
eases (mainly HIV) [25]. On the other hand, 
DC-based ‘negative’ immunotherapies aiming to 
reduce, suppress or redirect an existing immune 
response in autoimmune disorders and allergies 
is still in its infancy, but is gaining interest [26]. 
In this regard, we envisage that the adminis-
tration of DCs will be integrated as a substantial 
component of future, individualized treatment 
modalities, for a broad scope of medical fields. 
In this article, we will focus on the role of DCs 
in the (immune) pathogenesis and treatment 
of human disease, including cancer, infectious 
d iseases, autoimmune disorders and allergies.
DC-subsets
Dendritic cells were originally described by 
Steinman and Cohn [27]. Variations among the 
tissue distribution of DCs, and the differences 
in their phenotype and function, indicate the 
existence of heterogeneous populations of DCs. 
Indeed, several subsets of DCs have been char-
acterized and their fundamental role in either 
immunity or tolerance has been described [28].
In general, DCs are classified into two subsets: 
plasmacytoid (pDCs) and myeloid or conven-
tional DC (mDC or cDC), which show several 
distinct phenotypic and biological features [29]. 
While pDCs originate from a lymphoid progeni-
tor cell in lymphoid organs, a myeloid progenitor 
cell differentiates towards different DC popu-
lations in the bone marrow [30]. Subsequently, 
DC subsets circulate throughout the body: 
Langerhans cells (LCs) migrate towards the 
Figure 1. Dendritic cell maturation upon different stimuli and subsequent signals required 
for T helper cell differentiation. The distinct effector T cells derived from naive T helper cells are 
represented using a color-code strategy matching the DC subpopulation which provide the 
corresponding signals. 
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skin epidermis, while interstitial DCs migrate 
towards the skin dermis and various other tissues 
(airways, liver and intestines). Circulating and 
migrating DCs are found in the blood and in 
the afferent lymphatics, respectively.
In human blood, differences in DC subsets can 
be identified based on differential expression of 
TLRs [31], cytokine receptors and cytokines [32], 
as well as a difference in migratory potential [33]; 
indicating a different function in induction and 
regulation of the immune response (reviewed 
in [34]). pDCs express CD303 (BDCA-2), 
CD304 (BDCA-4) and CD123 (IL-3Ra) and 
release high amounts of type I IFN in response 
to viral stimuli [35]. In particular, BDCA-2+ 
pDCs are considered the front line in antiviral 
immunity owing to their capacity to rapidly pro-
duce high amounts of type I IFN in response to 
viruses [36]. Moreover, such pDC subsets demon-
strate an efficient cross-presentation of antigens, 
inducing both CD4+ and CD8+ antiviral T-cell 
responses [37], representing the optimal subset 
to be exploited for preventive and therapeutic 
antiviral vaccines. However, a second distinct 
subset of pDCs has been recently described that 
inhibits replication of cancer cells and kills them 
in a contact-dependent fashion [38].
On the other hand, cDCs are characterized 
by their expression of CD1c (BDCA-1), CD11c 
and HLA-DR, and can produce IL-12p70, 
IL-6, TNF-a and IL-10 in response to bacte-
rial stimuli and CD40 ligation [39]. Recently, 
several groups have characterized cDCs express-
ing CD141 (BDCA-3) as the human counter-
part of CD8a DCs in mice [40–43]. By contrast 
to human blood CD1c+ DC, the CD141+ DC 
subset is characterized by the expression of high 
levels of TLR3, but not TLR4, 5 or 7 [40], and 
displays the unique expression of the C-type 
lectin CLEC9A [41] and the chemokine receptor 
XCR1 [42,43]. In addition, CD141+ DCs produce 
high levels of IL-12p70, CXCL10 and IFN-b, 
and are of profound importance in the induction 
of T-cell responses by cross-presentation [40–43]. 
Although CD141+ DCs represent only 3–4% of 
all DCs in human blood, the data mentioned 
above suggest that CD141+ DCs will be the 
major human DC subset involved in the induc-
tion of cytotoxic T lymphocyte (CTL) responses 
against tumors and many pathogens.
In human skin, instead, two different mDC 
subsets have been characterized: epidermal LCs 
and dermal interstitial DCs (dermal DCs), with 
the latter subset further subdivided into CD1a+ 
DCs and CD14+ DCs [44]. In particular, human 
CD14+ dermal DCs induce naive CD4+ T cells 
to differentiate into cells with properties of fol-
licular helper T cells [45], which are the class of 
effector T helper cells that regulate the step-wise 
development of antigen-specific B-cell immunity 
in vivo [46]. 
On the other hand, LCs induce both CD4+ 
and CD8+ T cells and are more efficient in cross-
presenting peptides from protein antigens to 
CD8+ T cells. Moreover, CD8+ T cells primed 
by LCs acquire potent cytotoxicity, and are able 
to efficiently kill target cells, including tumor 
cell lines that express peptide-HLA complexes 
only at low amounts [45]. Therefore, the overall 
data suggest that dermal DCs would be more 
appropriate for vaccines aimed at inducing 
humoral responses, and LCs more appropriate 
for v accines aimed at inducing cellular responses.
DCs in human disease
 n Cancer
There is a clear link between cancer and inflam-
mation, confirmed by the presence of inflam-
matory cells, chemokines and cytokines in the 
early-stage tumor microenvironment [47]. DCs 
are also frequently present in the intra- and peri-
tumoral area [48], recruited by several chemo-
kines and cytokines [49,50], and contributing to 
either tumor growth or regression. 
Studies examining DC subset distribution 
in tumors have demonstrated that epithelial, 
stromal, marginal and peritumoral areas can 
harbor different DC types [51–55]. In particular, 
some studies have shown that high numbers 
of overall tumor-infiltrating DC are associated 
with improved outcome for patients with primary 
tumors [56–60], whereas other studies have shown 
that this is true only in the presence of specific 
DC subtypes, for example DCs positive for both 
CD1a and HLA-DR [55,61,62]. In addition to the 
number and subtype of infiltrating DCs, also the 
location of infiltration has also been shown to 
have a prognostic value, depending on the tumor 
type [52,54,55]. In patients with colorectal cancer, 
indeed, the presence of HLA-DR-positive DCs 
in the tumor stroma or CD1a-expressing DCs 
in the advancing edge has been correlated with 
an adverse survival outcome [54]. On the con-
trary, in patients with tongue carcinoma; peritu-
moral CD1a-positive DCs have been associated 
with improved patient survival and a reduced 
r ecurrence [63]. 
At present, the crucial role of DCs in the 
generation of protective antitumor immune 
responses has been established, and is related to 
their capacity to link innate and adaptive immu-
nity by presenting tumor-associated antigens 
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to T cells and inducing tumor-specific type 1 
T-cell responses [48]. Furthermore, the efficacy 
of inducing such type 1 T-cell responses by 
DCs also seems to be strongly dependent also 
on bi-directional cross-talk between DCs and 
NK cells [64].
However, the efficacy of antitumor immune 
responses mediated by DCs may be suboptimal 
given that, although proinflammatory cytokines 
can mature DCs, the most powerful danger sig-
nals for DC activation are PAMPs, which are 
absent if tumoral transformation is not virus-
induced [65,66]. Moreover, tumor cells and the 
tumor environment can hamper DC function 
through so-called immune escape mecha-
nisms [67]. Indeed, tumour-derived inhibitory 
factors might be involved in downregulating or 
altering DC function, which includes the inhi-
bition of DC differentiation, maturation, anti-
gen processing and migration out of the tumor 
into the lymph nodes [68–70]. In this regard, can-
cer patients have fewer circulating DCs [68,71–74] 
and intratumoral DCs are mostly characterized 
by an immature phenotype [51,68,69]. Immature 
DCs (iDCs) and immature myeloid cells are, 
indeed, recruited by tumor-derived factors 
(e.g., VEGF, IL-10, prostaglandin E2 (PGE2), 
COX-2 and gangliosides) and can directly sup-
press specific T-cell responses [68,71,72,75–78]. 
Moreover, the development of myeloid-derived 
suppressor cells and tumor-associated macro-
phages can contribute to DC inhibition, and 
further inhibit the immune containment of 
tumor growth [79–82].
The sum of such immune suppressive fac-
tors hampering the biological functions of DCs 
not only facilitates the tumor escaping from 
immune control, but also reduces dramati-
cally the success of cancer immunotherapy. In 
order for DC-based vaccines to be successful, 
highly immunostimulatory DCs are required 
to activate T cells and NK cells and simulta-
neous counteraction of immunosuppressive 
factors might be necessary to achieve optimal 
clinical benefit.
 n Viral infectious diseases
Viruses are one of the major targets of the 
immune system, and DCs are key determinants 
of the pathogenetic outcome of viral infections. 
Several PAMPs, such as the high repetition of 
capsomers and/or peplomers on virion surfaces 
and genomic viral RNA or DNA, are recog-
nized as markers of viral invasion by PRRs on 
DCs [2,7]. In particular, DCs play a key role 
not only in directly sensing the presence of 
pathogens, but also in orchestrating the inter-
actions between the other innate immune cell 
types, and facilitating the elicitation of anti-
viral defenses such as secretion of type I IFNs 
and defensins [26,28]. Moreover, the interaction 
between PRRs and components of microbes or 
viruses triggers a downstream signaling cascade 
whose end point is the activation of transcrip-
tion factors (e.g., IRF3, IRF7, AP-1 and NF-kB) 
inducing the activation of inflammatory cyto-
kine genes, such as TNF‑b, IL‑6, IL‑1b and 
IL‑12, as well as the upregulation of costimula-
tory molecules such as CD80, CD86 and CD40 
on DCs [83]. Viral antigens presented by DCs in 
the context of MHC class I will induce CD8+ 
CTLs, while those presented in the context of 
the MHC class II will induce CD4+ T helper 
cells. In the latter case, according to the pattern 
of cytokines secreted by DCs, antigen-specific 
activated CD4+ T helper cells can be directed 
into Th1, Th2 or Treg cell polarization, ulti-
mately driving the adaptive immune system 
toward either a cellular T cell (sustained by 
CD8+ CTLs), a humoral antibody or a tolerance 
response, respectively [84–89]. pDCs prevalently 
participate in the antiviral defense, inducing 
clonal expansion of T cells in lymph nodes [90], 
release of type I IFN [91] and antigen-specific 
CD8+ cytotoxic activity [37].
Several viruses have developed defensive strat-
egies in order to counteract the DC-mediated 
antiviral activity and to promote their own 
persistence, by favoring the production of Th1-
suppressive cytokines and altering cytokine 
secretion. Indeed, inducing a shift toward a 
Th2 response is known to cause detrimental 
effects by promoting inflammation, allergy and 
ultimately viral persistence [92,93]. Alternatively, 
viral infections may affect distinct stages of DC 
generation, from hematopoietic progenitor dif-
ferentiation to maturation [93–97], or interfere 
with antigen presentation process [97], thereby 
promoting viral spread by inhibiting the induc-
tion of efficient CTL responses that are crucial 
for viral control [98]. 
Furthermore, the numbers of and balance 
between the two subtypes of DCs seems to have 
a significant impact on the clinical outcome of 
viral infections. Severity of disease, indeed, 
has been found to be inversely correlated with 
the number of circulating pDCs and a blunted 
IFN-a release response during the early Phases 
of infection [99–101]. A reduced number of pDCs, 
besides individual genetic characteristics, may be 
virally determined, as shown in chronic hepati-
tis C virus [102] or HIV [103] infections. Finally, 
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viruses may replicate inside of DCs, perturbing 
or even subverting their physiology and giv-
ing rise to a more severe disease dependent on 
immunopathology [104–108].
 n Autoimmunity
Clinical autoimmunity arises as a result of an 
altered balance between the autoreactive cells 
and the compensating regulatory mechanisms. 
While T and B cells have been identified as the 
pathogenic effector cells in disease, the contribu-
tion of DCs in the initiation and perpetuation of 
inflammatory responses in autoimmune diseases 
is more and more being appreciated in the recent 
years [109–111]. Indeed, because of their commit-
ted antigen-presenting capacity and central 
role in the enhancement and regulation of cell-
mediated immune reactions, DCs are thought to 
play a pivotal role in the immunopathogenesis of 
several autoimmune disorders [21,112]. 
The main mechanisms whereby DCs induce 
and maintain peripheral tolerance include the 
generation of Treg cells from naive T cells and 
the expansion of pre-existing Treg cells, the 
release of IL-10 and other immune-regulatory 
cytokines, and the promotion of T cell anergy 
or depletion. The phenotype and functional fea-
tures of the different Treg cell populations have 
been extensively reviewed elsewhere [113–115]. 
Ohnmacht et al. confirmed a role for DCs in 
preventing autoimmunity under steady-state 
conditions, by constitutive ablation of all DCs 
subsets in mice, which resulted in breaking toler-
ance to self-antigens and development of spon-
taneous fatal autoimmunity [116]. In addition, 
depletion of pDCs during the acute or relapse 
Phase of experimental autoimmune encephalo-
myelitis, a mouse model for multiple sclerosis 
(MS), exacerbates the disease, underlining the 
regulatory role of DCs in limiting inflammation 
during autoimmunity [117].
Several studies have confirmed this involve-
ment by demonstrating accumulation of DCs 
at the site of inflammation, such as the synovial 
tissue and fluid in rheumatoid arthritis [118–120], 
the CNS in MS [121–124], and the salivary glands 
and conjunctiva of ocular surface in Sjögren’s 
syndrome [125]. Although, in some auto immune 
diseases, reduced circulating levels of DC sub-
sets have been observed in the peripheral blood 
of patients, this can likely be consequent to 
the recruitment or migration of DCs from the 
blood to the inflammatory site [118]. In that 
study, indeed, Jongbloed et al. demonstrated 
decreased expression of CD62L on DC in the 
synovial fluid of rheumatoid arthritis patients as 
compared with circulating DCs in the peripheral 
blood, indicative of migration. In addition, the 
chemokines CCL3, CCL4, CCL5 and CCL19 
are highly expressed in brain tissue of MS 
patients [126,127], and may play a role in chemoat-
tracting DCs (expressing the CCR5 and CCR7 
receptors) found in the peripheral blood, CSF 
and MS lesions of such patients [128,129]. The link 
between CCR5 expression and the clinical sever-
ity of MS is further supported by the observation 
that in MS patients expressing a truncated allele 
of the CCR5 gene and encoding a nonfunctional 
CCR5 receptor, the onset of MS is delayed [130] 
and the risk of recurrent clinical disease activity 
is decreased [131].
Furthermore, an altered phenotype and 
function of DCs in the peripheral blood and 
inflamed tissues of patients has been reported 
in several studies. In patients affected by sys-
temic lupus erythematosus (SLE), systemic scle-
rosis or Sjögren’s syndrome, pDCs are known 
to be hyperactivated and release high levels of 
IFN-a, in response to immune complexes con-
taining DNA- or RNA-bound to specific auto-
antibodies [132–135]. The IFN-a promotes the 
differentiation of monocytes into mDCs which 
in turn promote the expansion of autoreactive 
T cells [136]. By contrast, pDCs characterized 
by impaired maturation, decreased or delayed 
expression of activation markers and reduced 
secretion of type I IFN have been observed in 
MS patients [137,138]. Moreover, pDCs isolated 
from the CNS can actively suppress the abil-
ity of mDCs to promote Th1 or Th17 differ-
entiation [117]. One possible explanation for 
the discrepant results obtained in these studies 
is the existence of numerous subsets of DCs 
with opposite roles in promoting tolerogenic 
versus inflammatory responses. Indeed, two 
different subsets of pDCs have been recently 
reported in MS patients [139]: pDC1 (CD123high 
and CD58low) which promote the induction of 
IL-10 secreting T regulatory type 1 (Tr1) cells 
and are abundantly present in steady state con-
ditions, and pDC2 (CD123low and CD58high) 
that promote differentiation of Th17 cells and 
are present in higher numbers in inflammatory 
conditions. In addition, monocyte-derived DCs 
and freshly isolated mDCs from patients with 
SLE [140], RA [141] and MS [142–144] display upreg-
ulated levels of activation markers (i.e., CD86, 
CD80 and HLA-DR), whereas monocytes and 
mDCs from SLE patients and progressive MS 
patients fail to upregulate PD-L1, a negative 
costimulatory molecule [143,145]. Furthermore, 
this activated phenotype of monocyte-derived 
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DCs and mDCs is accompanied by an enhanced 
secretion of immune-modulatory cytokines, 
including IL-12p70, IL-18 and IL-23 [146–149].
The remarkable regulatory role of DCs, in 
terms of their ability to induce antigen-specific 
tolerance, makes them a very attractive target 
for development of cellular therapies in auto-
immune diseases. However, the pathological role 
of DCs, in terms of DC dysfunction reported 
in aforementioned investigations, imply that 
DC function needs to be restored in order to 
exploit the use of monocyte-derived DCs as an 
immuno therapeutic approach with regard to 
auto immunity. In this framework, novel strate-
gies that regulate DC development and differ-
entiation, in view of harnessing their tolerogenic 
capacity, are being developed. Indeed, a wide 
spectrum of biologicals and pharmaceuticals 
have the ability to differentiate tolerogenic 
DCs, both in vitro and in vivo. Based on this 
knowledge, vaccination with ex vivo modulated 
tolerogenic DCs as treatment modality for 
a utoimmune disorders is gaining momentum.
 n Role of DCs in allergic inflammation
Similarly to autoimmune disease, DCs are also 
suggested to contribute to the pathogenesis 
of allergic disorders. A significant rapid accu-
mulation of myeloid and pDCs to the inflam-
matory site after allergen challenge has been 
observed [22,150–152], which directly correlates 
with a rapid decrease of circulating DCs in the 
peripheral blood [153,154]. Observed in allergic 
children [155] and adults [156], especially in asth-
matic subjects. In addition, DCs from allergic 
patients have a more pronounced mature pheno-
type, such as higher expression of surface mark-
ers of DC maturity (CD83, CD86, HLA-DR 
and CD1c), which correlates with the heightened 
immune responsiveness [152,157,158]. Moreover, 
circulating DCs in children with allergic asthma 
produce a Th2-polarizing cytokine pattern upon 
TLR stimulation [159]. Allergens directly trigger 
PRRs on DCs which, upon allergen encounter, 
undergo maturation and migrate to the local 
lymph nodes in order to activate effector T 
and B cells [160–163]. In particular, it has been 
recently shown that TLR4 is the specific receptor 
for both airborne and contact allergens, such as 
the main house dust mite allergen, Derp2 [164], 
and nickel [165], activating the downstream sig-
nal transduction pathway and subsequent pro-
inflammatory cytokine production. The key role 
of inflammatory DCs in the allergic immune 
response is further underlined by the fact that 
their depletion at the time of allergen challenge 
abrogates all allergic manifestations in the air-
ways and intestine [166–168], which are restored by 
subsequent readministration of DCs [169].
DC-based therapeutic strategies
 n Immune-stimulatory DCs
The understanding of the pivotal role played 
by DCs in initiating the immune response and 
directing the adaptive immunity to foreign 
antigens allows a knowledge-based design of 
DC-based vaccine strategies (reviewed in [170]). 
This knowledge will help to targeting specific 
subsets, according to the desired outcome.
In order to develop DC-based immuno-
therapies, DCs can be generated in vitro either 
from CD34+ progenitor cells, derived from 
patients’ bone marrow or peripheral blood 
CD14+ monocytes; differentiation can be 
achieved using a cocktail of cytokines, lead-
ing to the generation of distinct DC subsets. 
Indeed, monocytes induced with GM-CSF and 
IL-4, IFN-a/b, TSLP, TNF or IL-15, differ-
entiate into GM-CSF/IL-4 DCs, IFN-a DCs, 
TSLP-DCs, TNF-DCs or IL-15 DCs, endowed 
with distinct functional characteristics [171]. Of 
note, melanoma-peptide-pulsed IL-15 DCs were 
shown to be much more efficient than IL-4 DCs 
in inducing antigen-specific CTL differentia-
tion in vitro [172], whereas IFN-a DCs showed 
improved activation of helper T cells [173]. 
Similarly, different DC maturation cocktails 
may significantly impact upon the capacity of 
DCs to elicit T cell immune responses [174]. 
Indeed, GM-CSF/IL-4 DCs activated with a 
cocktail of IFN-a, poly I:C, IL-1b, TNF-a 
and IFN-g, were shown to be much more 
effective in inducing specific CTLs than DCs 
matured with a cocktail of cytokines, including 
IL-1b, TNF-a, IL-6 and PGE2 (Figure 1) [175]. 
Subsequently, DCs loaded with antigens either 
as peptides, mRNA, tumor lysates or apoptotic 
debris, may lead to the generation of CD4+ and 
CD8+ T cell immune response [23,176].
 n DC-based cancer vaccines
The recent US FDA approval for sipuleucel-T, 
autologous PBMCs loaded with recombinant 
human prostatic acid phosphatase linked to 
GM-CSF, for therapeutic treatment of pros-
tate cancer [177,178], has represented a significant 
advancement in the field of cancer vaccinol-
ogy and a boost for new studies in the field of 
DC-targeted immunotherapy. The approval was 
based on results of randomized double-blind 
placebo-controlled multicenter trials, demon-
strating that patients who received sipuleucel-T 
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had a median overall survival of 25.8 months, 
compared with 21.7 months for patients who 
received the control treatment (p = 0.032; HR: 
0.775; 95% CI: 0.61–0.98). However, no dif-
ference in time-to-progression between the two 
groups was observed.
Undoubtedly, the increased overall survival of 
4 months in vaccinated patients, and the cost of 
approximately $US100,000 for the treatment, 
does not represent the optimal cost-effective 
scenario for a treatment. However, unlike sev-
eral previous attempts in the field, this is the 
Table 1. Phase I/II clinical trials for cancer using autologous monocyte-derived dendritic cells.










Melanoma Tumor lysate 10 id. 3/10 ND [248]
9 id. 1/9 ND [249]
40 id. 3/40 Yes [250]
50 id. Yes Yes [251]
38 id./sc. 9/33 ND [252]
Apoptotic tumor cells 16 id. 8/16 Yes [253]
10 id./iv. 3/10 Yes [254]
Gp100 peptides 12 iv. 2/12 Yes [255]




14 in./intralymph 0/14 Yes [257]
MART-1 peptides 16 id. 4/16 Yes [258]
Breast cancer Tumor lysate 12 sc. 2/12 Yes [259]
MUC-1 peptides 10 sc. NA Yes [260]
Lung cancer p53 54 sc. NA Yes [261]
Tumor lysate 15 id. 2/15 Yes [262]
Allogeneic cell line 14 id. 0/14 Yes [263]
Necrotic tumor cells 8 intranodal 2/8 Yes [264]
Renal carcinoma Tumor lysates 24 sc. 10/20 Yes [265]
9 sc. 6/9 Yes [266]
18 in. 9/18 Yes [267]
14 id. 1/12 ND [268]
MUC-1 peptides 20 sc. 6/20 Yes [269]
Colorectal cancer Tumor lysate 26 id. 4/17 Yes [270]
CEA DNA/mRNA 24 iv. 6/24 Yes [271]
14 sc./id. 1/12 Yes [272]
CEA peptides 10 in. 2/10 Yes [273]
Hepatocellular 
carcinoma
Tumor lysate 10 in. 3/7 Yes [274]
31 iv. 4/31 ND [275]
35 iv. 10/35 ND [276]
Glioma/glioblastoma Tumor lysate 10 id. 2/10 Yes [277]
24 id./intratumoral 4/24 Yes [278]
Tumor-derived 
peptides
12 id. 1/12 Yes [279]
22 in. 9/22 Yes [280]
Leukemia None 6 in. 0/6 Yes [281]
10 sc. 4/10 Yes [282]
Tumor lysate 12 id. 8/12 Yes [283]
WT 1mRNA 10 sc. 2/10 Yes [284]
More than 200 clinical trials have been performed using DC to modulate human disease. This table provides an overview after a systematic literature search from 
clinical trials that investigated clinical response and enrolled at least six patients.
DC: Dendritic cell; id.: Intradermal; in.: Intranasal; iv.: Intravenous; NA: Not applicable; ND: Not determined; sc.: Subcutaneous.
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first therapeutic cancer vaccine to demonstrate 
effectiveness in Phase III clinical trials, by pro-
longing the life of patients who have advanced to 
the late stage disease, metastatic, asymptomatic, 
hormone-refractory prostate cancer. It definitely 
shows the feasibility and effectiveness of thera-
peutic cancer vaccines and represents a starting 
point from which to move forward.
Indeed, the task of therapeutic vaccines in 
cancer requires overcoming the critical chal-
lenges represented by the quest for specific and 
selective tumor antigens and optimal delivery 
systems [179–186].
With respect to identify an optimal antigen 
delivery system, many different approaches are 
currently being pursued and those based on DCs, 
either by ex vivo loading or by in vivo targeting, 
are among these [170,187]. In particular, consider-
ing the distinct ability of the different subsets of 
DCs in inducing the two arms of the adaptive 
immunity, the exploitation of specific subsets of 
DCs to elicit the desired adaptive response is 
foreseen. As described previously, indeed, LCs 
are very efficient in cross-presenting peptides to 
CD8+ T cells, which acquire potent cytotoxicity 
and are able to efficiently kill target cells, includ-
ing tumor cell lines that express peptide-HLA 
complex, only at low amounts [45]. Such bio-
logical effects appears to be related to prevalent 
production and secretion of IL-15 cytokine [188]. 
In this framework, differentiation of mono-
cytes into DCs with cocktails including GM-CSF 
and IL-15 will generate cells with the phenotype 
and characteristics of LCs, which are far more 
efficient in vitro in priming melanoma antigen-
specific CD8+ T cells than DCs derived with 
GM-CSF and IL-4 [172,189]. Alternatively, IL-4 
DCs activated with a cocktail of IFN-a, poly I:C, 
IL-1b, TNF and IFN-g are able to induce signif-
icantly more melanoma-specific CTLs in vitro 
than DCs matured with the ‘standard’ cocktail 
of IL-1b, TNF, IL-6 and PGE2) [175].
However, results from multiple clinical tri-
als with DC-based cancer vaccines (Tables 1) 
have been contradictory and only fractions of 
the enrolled patients show potent antitumor 
immune responses (reviewed in [190–192]). Several 
reasons may account for this modest clinical out-
come, including the reproducible efficiency of 
DC generation, as well as the possible induction 
of adaptive CD4+ CD25+ Foxp3+ Treg cells in 
the presence of TGF-b or IL-10 derived from 
tumor microenvironment [81,193]. All such micro-
environment-immunosuppressive factors need to 
be considered and counterbalanced to hopefully 
improve the clinical outcome of cancer vaccines. 
Different strategies are currently being 
pursued in order to improve the efficacy and 
outcome of DC-based cancer vaccines. Along 
this path, indeed, chemotherapy drugs at low 
doses have been reported to increase DC func-
tion [194,195] and to enhance cross-priming for 
tumor antigens of apoptotic cancer cells [196]. 
In particular, low-dose cyclophosphamide selec-
tively increases migratory or pDCs, resulting 
in enhanced antigen presentation, augmented 
cytokine secretion and some inhibition of Treg 
cells [197]. Furthermore, it induces an increased 
expression of DC maturation markers [198] and 
regulates the production of type 1 IFNs; pro-
moting the evolution of the CD44high memory 
T-cell response [199]. Finally, it can condition 
the tumor microenvironment by modulating 
the expression of tumor antigens and accessory 
molecules of T-cell activation or inhibition [200]. 
An additional strategy is the exploitation of 
biological effects of TLR agonists, whose anti-
tumor affect was described many years before 
their actual discovery [201] and are listed (i.e., ago-
nists to TLR3, 4, 7/8 and 9) among the immu-
notherapeutic agents with the highest potential to 
treat cancer [202]. Such molecules, indeed, induce 
a series of effects on DCs which will ultimately 
lead to initiating T cell immunity (i.e., antigen 
uptake, processing and presentation, DC matu-
ration and T-cell activation [203]) for a potential 
anticancer therapy [204–206]. 
Although two TLR agonists, Bacillus 
Calmette-Guerin and imiquimod have been 
approved by the FDA for clinical use as monother-
apy for cancer [207–210], while others are in human 
clinical trials, of which several represent promising 
vaccine adjuvants as they are potent DC activa-
tors, augment T-cell responses and downregulate 
s uppressive effects of Treg cells (reviewed in [211]). 
 n DC-based vaccines for HIV
Because of the ability of DCs to prime potent 
adaptive immunity, the concept of DC-based 
therapeutic vaccination is also an attractive 
option for HIV [24,212]. In particular, several 
ongoing clinical trials are based on DCs ex vivo 
loaded with autologous HIV-1 antigens in the 
form of apoptotic cells, inactivated virus and viral 
RNA or DNA [25,213–215]. Both therapy-naive and 
highly active antiretroviral therapy (HAART)-
treated individuals have been enrolled in clini-
cal trials, in order to evaluate the impact of 
HAART on the immunotherapeutic strategies. 
Combined antiretroviral therapies (HAART), 
indeed, result in partial immune recovery [216], 
which should improve the immune response to 
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vaccines. Other authors believe it is better to vac-
cinate patients naive for therapy to maximize the 
endogenous antigen load and to minimize poten-
tially i mmunosuppressive effects of a ntiviral 
therapy [217].
The first human DC-based clinical trial was 
designed based on protein-pulsed autologous 
IL-4 DCs and tested in HIV-infected patients 
naive for HAART [218]. The administration of 
the formulation was well tolerated, enhancing 
HIV-specific T-cell reactivity, however, no effect 
on viral load was observed. 
A second human trial used ex vivo gener-
ated monocyte-derived IL-4 DCs loaded with 
aldrithiol-2 (AT-2)-inactivated virus, showing 
the efficacy of the immunotherapy using inac-
tivated virus and cytokine-matured DCs in 
patients with chronic HIV infection naive to 
HAART [219]. An effective HIV-1-specific T-cell 
response with sustained viral suppression of over 
90% was observed in almost 50% of vaccinated 
subjects (8/18), demonstrating that strong virus-
specific CD4+ T helper cells are necessary to 
induce and sustain virus-specific CD8+ effector 
functions. Interestingly, the therapeutic vaccine 
remained effective in close to half of the vacci-
nated patients a year after the vaccination, which 
demonstrated a direct correlation between the 
percentage of HIV-1-Gag-specific CD8+ T cells 
expressing perforin, and the decline in plasma 
viral load [220]. 
Similarly, a trial testing the efficacy of autol-
ogous DCs loaded with heat-inactivated virus 
was performed in patients under HAART. 
Partial control of viremia was observed for 
24 weeks after treatment interruption; how-
ever, the increased virus-specific CD4+ and 
CD8+ T-cell response was weak and tran-
sient [221]. Considering the discordant results 
in the two aforementioned clinical trials, the 
role of HAART or the effect of AT-2 inactivated 
virus versus heat-inactivated virus is still to be 
clarified. More recently, a clinical trial based on 
autologous DCs (IL-4 DC) pulsed with HIV 
peptides and influenza A matrix protein peptide 
was performed on HAART treated patients; the 
vaccine was safe and well tolerated, even though 
it did not show any significant effect on the viral 
load [222]. 
In addition, a clinical trial carried out to test the 
efficacy of viral mRNA-electroporated IL-4 DCs 
on HAART individuals demonstrated a prolifera-
tive response of CD8+ T cells to HIV antigens in 
seven out of nine treated patients [223]. The effect 
on viral load was not evaluated in this trial because 
the vaccinees did not undergo treatment interrup-
tion. Furthermore, a Phase I/II clinical trial based 
on monocyte-derived DCs loaded with a mixture 
of HIV-1 Gag, Pol and Nef antigen lipopeptides, 
covalently linked to a palmitoyl-lysylamide moi-
ety, is nearing completion [301], for therapeutic vac-
cination in c hronically HIV-1-infected patients on 
HAART (Table 2) [224].
 n Tolerogenic DCs
While immunogenic DCs have been used in 
clinical trials to mainly treat cancer patients, 
the undisputed role of DCs in the pathogenesis 
of autoimmune diseases opens new avenues for 
harnessing tolerogenic DCs for clinical appli-
cation. The use of DCs has become, indeed, a 
popular research track to repair and modulate 
autoimmunity, as well as to induce specific toler-
ance in organ transplants or allergy. DC-based 
immunotherapeutic strategies for autoimmune 
and allergic diseases can be developed either by 
targeting antigen to steady-state DCs in vivo, by 
modulating DC function in vivo or by cultur-
ing the cells in vitro, pulsing with antigen and 
injecting them back into patients. 
Table 2. Phase I/II clinical trials for viral diseases using dendritic cell-based immunotherapy.






Hepatitis B HBsAg 19 sc. Yes ND [285]
HBcAg 18–27 peptide and 
HBV PreS244–53 peptide
380 iv. Yes Yes [286]
Hepatitis C HCV-derived peptide 6 id. No Yes [287]
Human cytomeglovirus HCMV-derived peptide 24 sc. Yes Yes [288]
HIV-1 Heat-inactivated virus 24 sc. Yes Yes [289]
HIV-1 derived DNA/mRNA 29 sc. No Yes [290]
10 id. No Yes [223]
HIV-1-derived peptides 18 iv./sc. Yes Yes [222]
HBV: Hepatitis B virus; HCV: Hepatitis C virus; HCMV: Human cytomeglovirus; id.: Intradermal; iv.: Intravenous; ND: Not determined; sc.: Subcutaneous.
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Antigens coupled to antibodies specific for DC 
markers, such as 33D1 or DEC-205, have already 
been used in a mouse model to deliver antigens 
to DCs in vivo, resulting in antigen-specific toler-
ance which could not be broken by injection of 
the same peptide in the Freund’s adjuvant [225,226]. 
Alternatively, DC functions in vivo can be 
interfered either by suppressing immunogenic 
functions or by promoting tolerogenic activ-
ity. For instance, TNF-a blockers have been 
extensively used and validated as an efficacious 
treatment for RA, Crohn’s disease and psoria-
sis [227,228]. Although it remains to be established 
whether neutralization of TNF-a has a direct 
effect on DC function or cytokines produced by 
DCs, this approach clearly represents one of the 
greatest successes of immunology. In addition, 
the therapeutic efficacy of an anti-IL-12p40 
monoclonal antibody has been demonstrated 
in patients with active Crohn’s disease [229] and 
psoriasis [230,231], but not in MS patients [232]. 
Similarly, several new molecules have been 
identified that are able to alter DC function in 
allergic inflammation, resulting in immune tol-
erance and thus possibly leading to a long-lasting 
effect on the natural course of allergic disease. 
As an example, a specific small molecule com-
pound (VAF347) that interferes in vitro with 
the function of monocyte-derived DC was also 
shown to be effective in vivo in allergic airway 
inflammation in a mouse model of asthma [233].
Administration of iDC has already been 
shown to induce antigen-specific T-cell tolerance. 
Indeed, when iDCs pulsed with influenza matrix 
protein and keyhole limpet hemocyanin, a gen-
eral stimulator of CD4+ T cells, were injected, a 
decline in influenza-specific CD8+ IFN-g secret-
ing T cells was observed, while peptide-specific 
IL-10-secreting T cells appeared [234,235]. 
In this framework, an important issue to con-
sider when designing DC-based immunothera-
peutic strategies is that tolerogenic DC, after 
in vivo trafficking to the inflammatory micro-
environment, will receive maturation signals and 
will incite unwanted T-cell responses. Therefore, 
such side effect needs to be blocked. Several reports 
demonstrate that exposure to anti-inflammatory 
cytokines and immune-suppressive agents can 
condition DCs to a tolerogenic state [28]. DCs 
generated in the presence of anti-inflammatory 
factors, such as vitamin A, vitamin D3, PGE2, 
indoleamine 2,3-dioxygenase, IL-10, TGF-b, 
retinoids, hepatocyte growth factor and vasoac-
tive intestinal peptides display a stable tolerogenic 
pheno type that might be resistant to in vivo matu-
ration stimuli [236–242]. Recently, we have shown 
that the in vitro exposure to IL-10 of monocyte-
derived DCs from MS patients results in IL-10-, 
but not IL-12-secreting DCs with low expression 
levels of CD80/86 and an effective capacity to 
suppress myelin-specific T-cell responses in vitro 
[Cools et  al., Manuscript Submitted]. Importantly, 
further in vitro treatment of DC with matura-
tion stimuli did not induce phenotypic changes 
or modifications in the cytokine secretion profile. 
Aforementioned results suggesting that DCs can 
induce antigen-specific T-cell tolerance in vitro as 
well as in vivo, have prompted a number of groups 
to translate these findings into clinical application. 
A Phase I clinical trial using vitamin D3-treated 
tolerogenic DCs will be started in RA patients 
at Newcastle University (Table 3) [243,244,302]. 
Furthermore, the genetic manipulation of DCs 
by overexpressing immune regulatory molecules 
or inhibiting or silencing immune stimulatory 
molecules, promotes tolerogenic function. In line 
with this, a first safety study using tolerogenic DCs 
treated with antisense oligonucleotides targeting 
the primary transcripts of the CD40, CD80 and 
CD86 costimulatory molecules, has recently 
started at the University of Pittsburg [303].
Conclusion
Aforementioned investigations focusing on a 
better understanding of the role of DCs in the 
immunopathogenesis of these diseases will guide 
future research into the development of new and 
alternative therapeutic interventions. Indeed, 
dissecting the mechanisms of DC-activity in 
inflammatory conditions is invaluable in the 
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rational design of drugs and therapeutics that can 
reprogram the balance between immunity and 
tolerance, in the control of autoimmune d iseases, 
cancer and chronic infections.
The key role of DCs is not only in connecting 
the innate immunity and the adaptive immune 
response, but also in driving the type of effec-
tor immune response. Such a role is predomi-
nantly efficacious in protecting us from external 
(e.g., microbial pathogens) or internal (e.g., cancer 
cells) dangers. However, an excessive or misleading 
response may result in a pathogenetic effect, lead-
ing to autoimmunity or allergy. Considering such 
properties, DCs are being targeted as a therapeutic 
approach either to exploit their immunopotentiat-
ing activity (DC-based vaccine) or to inhibit their 
immunopathogenetic effects (antiallergic thera-
pies). In particular, the exploitation of the distinct 
immunological features of the different DC sub-
types should enable us to significantly improve the 
efficacy of vaccine strategies. However, the clinical 
effects of such strategies are still limited for the 
complexity of the immunoregulatory environ-
ment, which exerts a significant immune inhibi-
tion effect. Also, the first cancer immunotherapy 
approved for clinical use, sipuleucel-T, shows lim-
ited efficacy. Nevertheless, it represents an extraor-
dinary chance to acquire valuable information 
which will help to improving the immunological 
effectiveness and clinical outcomes of DC-based 
i mmunotherapeutic strategies. 
Future perspective
Dendritic cells have become an attractive cell type 
for therapeutic manipulation of the immune sys-
tem, in order to enhance insufficient immune 
responses in infectious diseases and cancer or to 
attenuate excessive immune responses in allergy 
and autoimmunity. Novel strategies to improve 
DC-induced tumor immune responses are under 
investigation. The recent identification that 
human CD141+ DCs to cross-present antigens has 
clear implications for the design of new therapies 
to treat cancers and infectious diseases with 
improved efficacy. However, although Poulin 
et al. [41] made a first attempt to delineate in vitro 
culturing conditions for the generation of CD141+ 
DCs from human progenitor cells, further opti-
mization of such protocols is necessary to allow 
for their use in adoptive transfer immunotherapy 
approaches. In addition, targeting antigen to the 
newly identified unique targets on CD141+ DCs 
(i.e., CLEC9A [41] and XCR1 [43]) will provide 
novel approaches to harness human DC subsets. 
Furthermore, depending on the type of anti-
gen, human DC subsets may cross-present for 
different functional outcomes, such as priming 
or tolerance [245]. This will be an important area 
for further investigation.
In addition, stronger activation and matura-
tion stimuli for DCs will boost research in this 
field, and it is likely that TLR ligands will play 
a major role in the development of new vaccine 
adjuvants in the 21st century.
The prospected enhanced therapeutic value 
in patients of these ex vivo selective generated 
DC-vaccines needs to be proven. However, such 
observations may have a great impact to assess 
the specific immune responses elicited in vivo 
targeting selective DC subsets by using antigens 
linked to specific anti-DC receptor antibodies. 
Preclinical studies, indeed, demonstrate that the 
specific targeting of antigens to selective DC sub-
set in vivo results in considerable potentiation of 
antigen-specific T cell immunity [226,246,247], sug-
gesting that such s trategy could be successfully 
translated into humans.
In conclusion, we anticipate that novel 
DC-based vaccination strategies will most likely 
be focussed on a multitargeted approach, based on 
a better understanding of DC biology in order to 
attain the goal of effective immunotherapy in can-
cer. In addition, vaccination with tolerogenic DCs, 
in combination with regulatory T cells, might gain 
clinical interest in the treatment of autoimmune 
disorders and allergy.
Executive summary
  Although the exact genesis and development of the different types and subsets of dendritic cells (DCs) has not yet been fully delineated, 
differences in the expression of various molecules predicts that they have different functions. This is supported by recent groundbreaking 
work on the subdivision of human DC into subsets and the investigation of their respective functions.
  Alteration in the number, phenotype and/or function of dendritic cells has been observed in inflammation, such as in cancer, infectious 
diseases and autoimmune immunopathological diseases in humans. These observations underline the central role of DCs in maintaining 
the delicate balance between immunity and tolerance.
  By elucidating the means for ex vivo generation and modulation of distinct DC subsets, DC-based therapeutic strategies have gained 
momentum both in order to ameliorate and attenuate immune responses. However, many questions remain to be answered and future 
research is warranted.
  Combination of DC-based therapeutic vaccines and adjuvanting strategies to counteract the immunosuppressive tumor 
microenvironment should significantly improve the clinical outcome.
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